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Zusammenfassung 
 
Brain Acid-Soluble Protein 1 (BASP1) ist ein intrinsisch unstrukturiertes Protein, das 
in Mechanismen wie dem Auswachsen und der Plastizität von Neuronen involviert ist und vor 
kurzem als Co-Suppressor des Wilms’ tumor suppressor protein 1 (WT1) entdeckt wurde. 
Diese Co-Suppressor Aktivität wird durch Interaktion von BASP1 mit der WT1 
Suppressions-Region vermittelt. Außerdem wurde eine Änderung der subzellulären 
Lokalisation von BASP1 in HeLa Zellen nach Induktion von Apoptose festgestellt.  
Ein neu entwickelter Algorithmus (Robert Konrat), der Proteine aufgrund ihrer so 
genannten Meta-Struktur untersucht, prognostiziert für eine 20-40 Aminosäuren lange Region 
von BASP1 eine große Wahrscheinlichkeit für Protein Interaktion. Auch die Sekundärstruktur 
des interagierenden  Proteins (bzw. des relevanten Teils des Proteins) kann durch die Meta-
Struktur Analyse vorhergesagt werden. Im Fall von BASP1 interagiert die genannte Region 
wahrscheinlich mit einem Loop oder einem β-Faltblatt Segment eines anderen Proteins. 
Damit übereinstimmend, prognostiziert Meta-Struktur Analyse eine Loop oder β-Faltblatt 
Konformation und eine hohe Wahrscheinlichkeit für Protein Interaktion für die Suppressions-
Region von WT1. Folglich stimmt Meta-Struktur Analyse mit der beobachteten Interaktion 
zwischen BASP1 und WT1 überein. 
Aktuelle Studien konstatierten eine differentielle Expression von BASP1 in MC29 
transformierten Zelllinien embryonaler Fibroblasten von Huhn und Wachtel. Das MC29 Virus 
codiert für das onkogene v-Myc Protein, welches nach Infektion der Zelllinie überexprimiert 
wird und schlussendlich, schon auf Ebene der Transkription, zur Repression von BASP1 
führt. Überraschenderweise, hindert ektopische Expression von BASP1 in MC29 infizierten 
Zellen die Transformation der Zellen durch v-Myc. Andere Studien mit einem so genannten 
„cell penetrating peptide“ (ein Peptid, das die Zellmembran penetrieren kann), das ein 20 
Aminosäuren langes Segment der prognostizierten Protein Interaktions Region von BASP1 
beinhaltet, konstatierten einen starken „zell-schwächenden“ Effekt (cytopathic effect) dieses 
Peptids auf embryonale Hühner-Fibroblasten. Dieser Effekt war weitaus stärker in MC29 
transformierten als in untransformierten embryonalen Hühner-Fibroblasten. Dieses Resultat 
betont die Funktionalität des kleinen interagierenden Segments von BASP1. Die Hypothese 
wurde aufgestellt, dass die wechselseitige Hemmung der Proteine BASP1 und Myc 
möglicherweise auf direkter Interaktion zwischen diesen zwei Proteinen basiert. 
Obwohl die N-terminale Transaktivierungsdomäne (TAD) von Myc Proteinen sehr 
unstrukturiert ist, wurden sowohl α-helikale Bereiche als auch β-Faltblatt Segmente 
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vorausgesagt. Myc TAD kann mit vielen auch strukturell unterschiedlichen Proteinen 
interagieren. Diese spezifischen Interaktionen werden oft durch unterschiedliche Bereiche von 
TAD vermittelt. 
Das Ziel dieser Studie war die direkte Interaktion zwischen dem bereits genannten 
Interaktions-Peptid von BASP1 und einem N-terminalen Teil von v-Myc (enthält c-Myc TAD 
vom Huhn), dem gesamten v-Myc Protein bzw. dem c-Myc Protein (Huhn) zu untersuchen. 
Dies wurde versucht mittels His6 Pull-Down Experimenten und Bindungsstudien mithilfe 
analytischer Gelfiltrations-Säulen.  
Schlussendlich konnte direkte Interaktion zwischen Myc und BASP1 mit den 
genannten Methoden nicht nachgewiesen werden. Folglich bleibt der Mechanismus der 
wechselseitigen Beeinflussung dieser zwei Proteine weiterhin unklar.  
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Abstract 
 
Brain Acid-Soluble Protein 1 (BASP1) is an intrinsically unstructured protein, which 
is involved in neuronal sprouting and plasticity and has also been identified as a cosuppressor 
for the Wilms’ Tumor suppressor protein 1 (WT1). This cosuppressor activity is mediated via 
binding of BASP1 to the WT1 suppression region. Moreover, the subcellular localization of 
human BASP1 is altered upon induction of apoptosis in HeLa cells.  
A novel bioinformatical approach, based on the Meta-structure concept (Robert 
Konrat), predicts a small stretch of 20-40 amino acids of chicken BASP1 with a high 
probability for interaction with other proteins, presumably with a loop or β-stranded part of a 
protein. In agreement with this finding, meta-structure analysis of WT1 predicts for its 
suppression region a loop or β-stranded conformation and a high probability for protein 
interaction. Hence, the Meta-structure approach is in agreement with the observed interaction 
between BASP1 and WT1. 
Current studies found chicken BASP1 to be differentially expressed in MC29-
transformed avian embryonic fibroblast cell lines. The MC29 virus encodes oncogenic v-Myc, 
which leads to the repression of BASP1 already at the transcriptional level. Surprisingly, 
ectopic expression of chicken BASP1 in MC29 infected chicken embryonic fibroblasts 
hinders the transformation of the cells by v-Myc. In addition, a synthetical cell penetrating 
peptide comprising a 20 residue long stretch of the predicted protein interaction site of 
BASP1 led to a cytopathic effect in chicken embryonic fibroblasts (CEF). This effect was 
more stringent in MC29 transformed than in untransformed CEF, highlighting the 
functionality of this small interacting stretch of BASP1. It was hypothesized that the mutual 
suppression of Myc and BASP1 might be a consequence of direct interaction between those 
proteins. 
The N-terminal transactivation domain (TAD) of Myc proteins, although highly 
unstructured, was proposed to harbour α-helical as well as β-stranded segments. Myc TAD is 
able to interact with a lot of even structurally different proteins. These specific interactions are 
often mediated by different parts of Myc TAD. 
The aim of this study was to investigate direct interaction between the small 
interacting peptide of BASP1 and an N-terminal part of v-Myc (harbouring chicken c-Myc 
TAD), full-length v-Myc and chicken c-Myc, respectively, with the help of His6 pull-down 
assays and binding studies by analytical size exclusion chromatography.  
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As a matter of fact, we were not able to observe direct interaction between Myc and 
BASP1 with the used methods, indicating that the mutual repression between those proteins 
remains still unclear. 
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Abbreviations 
 
2nd IA secondary structure of the interactor 
Amp ampicillin 
APS ammoniumperoxodisulfate 
BASP brain acid-soluble protein 
BCIP 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt 
BIRPs BASP1 immunologically related proteins 
bHLHZip basic region/helix-loop-helix/leucine zipper 
bp base pair 
CaM calmoduline 
CoA chloramphenicol 
cDNA complementary DNA 
CIP calf intestinal alkaline phosphatase 
C-terminus carboxy terminus 
CV column volume 
Da dalton (1/12 of the mass of a 12C atom) 
DNMT DNA methyl transferase 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
Fc fragment crystallizable (base of the antibody) 
fw forward primer 
Gag group-specific antigen 
GB1 B1 Ig binding domain of streptococcus 
GST glutathione-S-transferase 
HAT histone acetyl transferase 
HDAC histone deacetylase 
His6 tag six consecutive histidine residues 
IMAC immobilized metal ion affinity chromatography 
IPTG isopropyl-β-D-thiogalactoside 
IUP intrinsically unstructured protein 
kb kilo base 
LB media Luria-Bertani media 
MB I-III Myc (homology) box I-III 
MBP maltose-binding protein 
MC29 myelocytomatosis retrovirus 29 
MM1 Myc modulator-1 
myr myristoyl-group 
NBT p-nitro blue tetrazoliumchloride 
NOE nuclear Overhauser effect 
N-terminus amino-terminus 
OD600 optical density (absorbance) at 600nm  
O-GlcNAc O-linked N-acetylglucosamine monosaccharides 
PAGE polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
PEST peptide sequence rich in proline (P), glutamic acid (E), serine (S) and 
threonine (T) 
PI3K phosphoinositide-3-kinase 
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PKC protein kinase C 
PPI probability for protein interaction 
ppm parts per million 
PtdIns(4,5)P2 phosphatidylinositol (4,5)-bisphosphate 
rev reverse primer 
rpm revolutions per minute 
RSV rous sarcoma virus 
SDS sodium dodecyl sulfate 
SID mSin3-interaction domain 
TBP TATA box-binding protein 
T-D T-box DNA binding domain 
TAD transactivation domain 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TEV tobacco etch virus 
TFE trifluoroethanol 
Tm melting temperature 
TRD transrepression domain 
Tris trishydroxymethylaminomethane 
trx thioredoxin 
U unit 
WT1 Wilms’ tumor suppressor protein 1 
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Introduction 
 
 
The Meta-Structure Concept 
 
The Meta-Structure Concept was developed by Robert Konrat with the aim to extract 
information about protein structure and function out of the primary sequence of a protein 
without the help of 3D structural information, which often, even at high resolutions, is 
insufficient to predict protein function or functional sites. Individual residues are treated as 
tightly interacting chemical entities and their mutual interdependences can be quantified using 
parameters borrowed from network theory. Finally meta-structure analysis from the primary 
sequence of a protein gives information about the compactness of a protein (whether proteins 
are highly structured, unstructured or partially folded). It can be used for the search of protein 
fold topology similarities (meta-structure homologues), which are not necessarily visible in 
the primary sequence of proteins. Furthermore, it is able to predict protein interaction and 
ligand binding sites [2]. 
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Cell Cycle Control 
 
The homeostasis of a multicellular organism depends on a tight control of the cellular 
behaviour of single cells. Each cell corresponds to a complex mixture of extracellular as well 
as intracellular signals, which regulates processes as cell growth, cell proliferation, cell 
differentiation and apoptosis. Multiple interconnected signal transduction pathways transfer 
information to the nucleus, where a network of proteins (transcription factors, chromatin 
remodelling complexes, proteins of the basic transcriptional machinery, etc.) lead to the 
transcription of genes in response to those signals. A number of pathways exist, which ensure 
the integrity of the cell, especially the genome of the cell before cell division. Those internal 
checkpoint control mechanisms are triggered by events as DNA damage and can stop the cell 
cycle at certain checkpoints. The ability to repair those damages decides the fate of the cell. 
Fig. 1 shows a schematic representation of the cell cycle. 
 
 
If constituents of those pathways are deregulated, the reception and transmission of 
signals are disturbed; hence there is no proper response. As a result, the balance between cell 
division and cell death is affected and may eventually – if not recognized – lead to 
uncontrolled cell proliferation and tumor growth. The so-called transformation of cells to a 
tumorigenic state can be caused by the activation of proto-oncogenes as well as the 
deactivation of tumor suppressor genes. The products of proto-oncogenes are important 
constituents of signaling pathways regulating cell proliferation and therefore have oncogenic 
potentials. Important proto-oncogenes, which are deregulated in many human tumors, are 
 
 
Fig. 1. The cell cycle. G1: Gap 1 
phase; S: Synthesis phase; G2: 
Gap 2 phase; M: Mitosis; G0: 
resting phase. During the Gap 
phases and Synthesis phase the 
cell is producing proteins, RNA, 
etc. (G1, G2) and replicates its 
genome (S). The G0 phase 
indicates a resting phase, where 
the cell no longer divides (e.g. 
after terminal differentiation). 
Dotted lines indicate certain 
checkpoints during the cell cycle, 
at which the cell cycle can be 
halted, e.g. to repair possible 
damages. At those checkpoints 
the cell might decide to undergo 
apoptosis. 
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myc, ras and jun. A lot of these proto-oncogenes have been discovered as the cellular 
homologues of viral oncogenes. 
 
 
Oncogenes and Viruses 
 
Oncogenes were first discovered in DNA tumor viruses as the genes responsible for in 
vivo and in vitro neoplastic transformation observed with such viruses. Examples of such 
oncogenes are the large T (tumor) antigen, ‘middle’ T antigen, E7 gene and E1A gene of 
polyoma, SV40, papilloma and adenoviruses, respectively. The products of those genes rely 
on the cooperation of other cellular oncogenes to establish a fully transformed phenotype [3]. 
Another group of oncogenes had been identified as transforming alleles in the 
genomes of replication defective RNA tumor viruses. Interestingly, these genes do not exist in 
replication competent RNA tumor viruses, although they may induce neoplastic tumor 
formation in vivo by a distinct mechanism [3]. Oncogenes from replication defective RNA 
tumor viruses have homologous genes in cells, called proto-oncogenes. Therefore it was 
hypothesized that those viruses picked up a cellular gene via recombination during their 
evolution and that this gene was altered either by subsequent mutation or already at the 
recombination event, possibly leading to the fusion of a viral protein with the cellular proto-
oncogene. One of the first oncogenes characterized was the v-src gene of Rous Sarcoma virus 
(RSV) [4]. The v-myc oncogene was discovered in the acute Myelocytomatosis retrovirus 
MC29 as being responsible for transformation [5-7]. The Harvey murine sarcoma virus (Ha-
MuSV) RNA genome has been shown to contain an approximately 4.5 kb insert of rat genetic 
sequences, which codes for the nonvirion phosphoprotein p21 (v-ras) [8, 9]. The Avian 
Sarcoma virus 17 (ASV17) carries the v-jun oncogene [10].  
A lot of oncogenes from tumor viruses as well as from tumors have been characterized 
so far. Moreover, the functions of the respective proto-oncogenes in ‘healthy’ cells are of 
great interest in order to better understand the mechanisms underlying neoplastic 
transformation and also normal cell physiology. 
Proto-oncogenes have all in common that they encode proteins, which are members of 
the signaling cascade regulating genes and proteins involved in cellular proliferation and 
differentiation. If proto-oncogenes transform to oncogenes via different mechanisms (e.g.: 
mutation, translocation, etc.), cells are not able to respond or not properly respond to signals, 
which control these processes, anymore, consequently leading to a cancerous state. 
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The myc gene family 
 
The myc gene family encodes transcription factors, which are implicated in a lot of 
different pathways controlling cell behaviour and therefore have a high oncogenic potential. A 
lot of research is interested in the structural features of Myc proteins leading to their 
tremendous functional diversity. Myc transcription factors interact with a lot of different 
proteins in a specific manner either via their N-terminal transactivation domain (TAD) or the 
C-terminal ‘basic region/helix-loop-helix/leucine zipper’ motif (bHLHZip) and are able to 
either activate or repress transcription of different genes depending on the cellular context.  
The research on myc genes started with the discovery of the highly oncogenic v-myc 
encoded in the proviral genome of the acute transforming Myelocytomatosis retrovirus 
(MC29), which was isolated in 1964 from a chicken with spontaneous myelocytomatosis [11]. 
The protein encoded by v-myc induces tumor formation in MC29 infected chicken [12, 13] 
and can transform several different lineages of mammalian and avian cells either alone or in 
cooperation with other oncogenes [14]. The v-myc sequence was later on found to occur also 
in other retroviral isolates CMII, MH2, OK10 and FTT [15-19].  
 
 
The proto-oncogene myc 
 
The c-myc proto-oncogene, which is the cellular homolog of v-myc, was discovered in 
chicken [20, 21], what led to the conclusion, that v-myc was derived from the cellular c-myc 
by retroviral transduction. In fact, sequence alignments of the MC29 proviral genome with the 
nondefective helper virus (MC29-associated virus) and cellular chicken c-myc, showed that 
the MC29 virus arose by recombination of the nondefective helper virus with cellular 
sequences present within the normal chicken genome [1]. Fig. 2 shows an alignment of MC29 
v-myc, chicken c-myc and RSV gag and env sequences indicating the 5’ and 3’ recombination 
junctions between v-myc and c-myc. 
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In mammals, the myc gene family comprises 5 related genes, c-myc, N-myc, L-myc, S-
myc and B-myc. c-myc, N-myc and L-myc all have the same three-exon and two-intron 
structure, where the first exon appears to have regulatory function, whereas polypeptide 
coding regions lie in exons 2 and 3. Interestingly, removal of the first exon/intron enhances 
the oncogenic potential [22]. The S-myc gene is an intronless gene, which is most similar to 
the second and third intron of N-myc [23]. B-myc consists only of second exon sequence and 
is most homologous to c-myc [24].  
As c-Myc is involved in so many fundamental processes regulating cell behaviour, the 
expression of c-myc is tightly regulated by different transcription factors, signal transduction 
pathways and feedback loops that activate or repress c-myc transcription [25]. The promoter 
region of c-myc harbours two transcription initiation sites upstream of exon 1, together with 
regulatory sequences, which are necessary for normal promoter function in eukaryotes [26]. A 
short region of 40 base pairs – highly homologues to N-Myc – lies proximal to the second 
promoter P2 of c-myc and harbours an E2F-site bound by E2F transcription factors, which is 
overlapping with a transforming growth factor TGFβ inhibitory element (TIE), which 
mediates down-regulation of c-myc via Smad proteins [27-29]. In addition, several proteins 
including the zinc finger protein MAZ, the homeodomain protein CUT and Sp1 can bind to a 
GC-rich element termed ME1a1 [30-32]. Moreover, c-myc is target of NFκB [33, 34] and can 
be repressed as well as activated by the WT1 tumor suppressor protein [35, 36]. Multiple 
mitogenic signals activate c-myc expression, for example v-Abl via the Ras/Raf2-signaling 
cascade and PDGF via Src/Vav2/Rac [37-40], whereas anti-mitogenic signals as TGFβ, APC, 
glucocorticoids and interferon γ (IFNγ) repress c-myc expression [41-45].  
Other mechanisms of c-myc regulation involve DNA stretches that are bound by 
different proteins in their single-stranded and double-stranded state, respectively. The CT 
element just upstream of promoter P1 consists of 5 imperfect repeats of the sequence 
Fig. 2. The 5’ and 3’ recombination junctions between v-myc and chicken c-myc indicating the recombination 
event between the nondefective helper virus and chicken c-myc. RSV gag and env sequences were used for 
the alignment to chicken c-myc and MC29 v-myc. Vertical lines indicate homologous sequences (adapted 
from Reddy et al. 1983 [1]) 
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CCCTCCCCA. It is bound by Sp1 when double stranded, but when single stranded, the 
pyrimidine-rich strand is bound by heterogeneous nuclear ribonucleoprotein K (hnRNP K), 
while the purine-rich strand is bound by the cellular nucleic acid binding protein (CNBP) 
[46]. In addition, a 27-bp region of this purine-rich strand located –142  to –115 upstream of 
promoter P1, the nuclease hypersensitivity element III1 (NHEIII1) [47], comprises guanine-
rich tracts capable of forming G-quadruplexes that function as silencer element [48]. G-
quadruplexes have been found in a lot of promoter regions spanning 1 kb upstream of 
transcription start sites of genes [49]. Interestingly, systematic algorithmic searches for 
guanine-rich tracts found putative G-quadruplex-forming sequences to be prevalent in proto-
oncogenes but essentially lack in tumor-suppressor genes [50]. Moreover, an increasing 
number of proteins have been identified that is able to interact with G-quadruplexes as well as 
promote or non-catalytically disrupt G-quadruplex formation [51-53]. The NHE III1 in the c-
myc promoter has been shown to control 80-90% of its transcriptional activity [54].  
The Far UpStream Element (FUSE) of the c-myc gene is an extended, largely AT-rich 
segment, which is located more than 1500 base pairs upstream of the c-myc promoter. It is 
bound by FUSE binding proteins (FBPs), which bind sequence-specifically to single-stranded 
DNA [55]. FBPs act as transcriptional activators via interaction with the subunits of TFIIH 
p62, p80/XPD and p89/XPB [56]. The FBP interacting repressor (FIR) is a repressor of 
activated transcription and binds to FBP as well as single-stranded DNA. FIR, like FBP, 
interacts with the TFIIH subunit p89/XPB but opposes FBP function [57]. The Myc target 
gene p38 is another FBP binding partner [58], which targets FBP for ubiquitylation and 
subsequent degradation; hence the FBP/Myc/p38 system is an example for a classical 
homeostatic end-product feedback loop [59]. The FBP/FIR system together with melted 
FUSE might be a possible control mechanism for the intensity of on-going transcription [59] 
considering the fact that torsional forces generated by the RNA polymerase are powerful 
enough to melt susceptible sequences such as FUSE [60].  
c-myc is expressed in practically all cells of embryonic and adult tissues during 
proliferation, as well as in a wide variety of malignancies of different cell types. Contrary, the 
expression patterns of N-myc and L-myc appear to be more restricted to certain types of 
tissues and depending on the developmental stage. Consistent with this, they were found to be 
expressed only in a restricted set of tumors. N-myc was found in neuroblastomas, whereas L-
myc was isolated from small-cell lung carcinomas [61-63]. 
The study of the myc gene family intensified after the realization that these genes are 
not only key regulators of cell proliferation, differentiation and apoptosis, but they decisively 
 17 
regulate many different aspects of cell behaviour. This potency requires a highly controlled 
expression of the members of this gene family. Deregulation of myc genes contributes to the 
genesis of many human tumors, in which an elevated expression level of myc mRNAs has 
been stated [64]. Most striking, it was discovered that enhanced expression of Myc proteins 
contributes to almost every aspect of tumorigenesis [65]. It had long been recognized, that 
Myc proteins can drive unrestricted cell proliferation [66] and inhibit cell differentiation [67], 
but recently it was shown, that deregulated expression of myc can drive cell growth [68, 69] 
and vasculogenesis [70], reduce cell adhesion [71, 72], and promote metastasis [65] and 
genomic instability [73]. There are several different molecular mechanisms underlying a 
deregulated state of myc genes, as gene amplification, gene translocation or mutations 
affecting for example post-translational modification of the N-terminal transactivation domain 
(TAD). For example, c-myc gene translocations and substitution mutations of residue Thr58 
in c-Myc TAD are often found in Burkitt’s lymphoma [74, 75]. Thr58 is an in vivo 
phosphorylation site and the major O-GlcNAc glycosylation site of c-Myc. Moreover, it is 
altered to a methionine or alanine in four different retroviral strains [76, 77]. Mutation of 
Thr58 therefore prevents regulation by posttranslational modification [78, 79]. Amplification 
of N-myc is associated with neuroblastoma [80]. 
 
 
 
 
The Myc/Max/Mad network 
 
The common feature of proteins of the Myc/Max/Mad network is the ‘basic 
region/helix-loop-helix/leucine zipper’ (bHLHZip) motif, which allows DNA binding, 
dimerization with other members of the network as well as interaction with other proteins. 
Myc has not been found as a monomer in vivo but bound to its partner protein Max (Myc-
associated factor X). The characterization of Max initiated the search for other proteins with a 
bHLHZip domain and led to the identification of the Mad proteins Mad1, Mxi1, Mad3 and 
Mad4 [81, 82] and two additional proteins Mnt and Mga [83, 84], which are able to 
heterodimerize with Max. Mad proteins and Mnt share, apart from the bHLHZip motif, an 
mSin3 interaction domain (SID), which mediates transcriptional repression [85-87]. Mlx, a 
Max-like protein, was identified soon afterwards and is able to heterodimerize with Mad1, 
Mad4 and Mnt [88, 89] and further extends the network to the Mlx binding proteins MondoA 
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and WBSCR14 [90, 91]. Functional homodimerization is only observed with Max and Mlx. 
Homodimers and heterodimers of the network function as DNA binding competent complexes 
and recognize the same DNA sequence (CACA/GTG), which is a subset of the general E-box 
DNA sequence (CANNTG) that is bound by all bHLH proteins [92, 93]. The currently known 
proteins of the Myc/Max/Mad network are depicted in Fig. 3 with Max and Mlx as central 
components. 
 
 
 
 
 
Transcriptional regulation of Myc/Max/Mad network proteins is thought to affect the 
chromatin structure of gene loci and a lot of proteins have already been described to interact 
with Myc, which are parts of chromatin remodelling complexes (e.g. TRRAP, TIP48, TIP49, 
etc.). TRRAP is a core subunit of the TIP60 and GCN5 histone acetyltransferase (HAT) 
Fig. 3. The Myc/Max/Mad network. All constituents of the network have a bHLHZip domain, which is 
needed for homo- and heterodimerization. Arrows indicate the known interactions between the network 
members. Heterodimerization is marked by double arrows. Homodimerization of Max and Mlx is marked by 
grey curved arrows. Additional domains are indicated by small boxes. TAD: transactivation domain; SID: 
mSin3-interaction domain; T-D: T-box DNA binding domain; TRD: transrepression domain. The TAD of 
Myc proteins is also involved in transcriptional repression. As far as characterized the members of the 
network function as regulators of different aspects of cell behaviour as indicated. 
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complexes [94] and its interaction with Myc is dependent on the integrity of a conserved 
domain in c-Myc TAD, Myc box II. Subsequent histone acetylation of responsive promoters 
leads to enhanced gene expression [95, 96]. Interestingly, TRRAP is also a constituent of a 
complex containing the p400 E1A-binding protein, whose Drosophila and yeast homologues, 
Domino and Swr1, are histone exchange factors [97, 98]. Conversely, Mad proteins recruit 
repressor complexes, which contain histone deacetylase (HDAC) activity, through their SID 
domain. The antagonism of Myc and Mad proteins is supported by the fact that Myc proteins 
are present in proliferating cells, whereas Mad proteins are expressed in non-proliferating, 
differentiated cells [81, 82].  
As a matter of fact, an increasing number of studies find Myc also to repress 
transcription of certain genes. For example, Miz1 can tether the Myc/Max heterodimer to core 
promoters devoid of E-boxes, what eventually leads to gene repression [99-104]. 
Furthermore, Myc has been found at other core promoters that lack E-box sequences and not 
in combination with Miz1. Therefore it is hypothesized that Myc can be recruited by other 
proteins to their cognate DNA-binding sites [105]. Possible candidate proteins, which might 
act as Myc tethering factors, are specificity protein-1 (Sp1) [106], nuclear factor Y (NF-Y) 
[107], transcription factor II-I (TFII-I) [108] and yingyang-1 (YY1) [109].  
Furthermore, proteins exist that influence activator and/or repressor roles of Myc. 
p19ARF is able to bind to Myc and inhibits its ability to activate transcription, but seems to 
leave repression by Myc unaffected [110, 111]. 
The list of proteins directly interacting with Myc is growing and strikingly, it’s not 
possible to separate Myc domains into classical DNA-binding domain and transcriptional-
effector domain, as interaction with proteins does occur at the N-terminal TAD as well as at 
the C-terminus. Prominent proteins that interact with the C-terminus of Myc and lead to 
transcriptional activation are CREB-binding protein (CBP) and p300 that have histone 
acetyltransferase activity [112]. Moreover, recruitment of the DNA methyltransferase 3a 
(DNMT3a) to Myc-Miz1 complexes has been observed, suggesting a possible Myc induced 
repression mechanism via DNA methylation of target promoters [113]. 
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Myc target genes 
 
A lot of genes harbour E-box sequences in their promoter sequence and are therefore 
potential Myc target genes. As Myc is even recruited to core promoters lacking E-box 
sequences the list of potential target genes becomes even greater. The question is now, which 
genes influenced by Myc are crucial targets. Furthermore to consider is the fact that Myc 
influences indirectly the expression of genes through the transcriptional activation of factors 
which themselves regulate gene expression.  
Myc target genes have been identified in developmental pathways. Myc regulates the 
transcription of cyclin D2 and the cell-cycle inhibitor p18INK4c (might not be a direct target by 
Myc), which regulate the proliferation and differentiation of neuronal precursor cells [114]. 
Cyclin D1, cyclin D2 and E2F2 are regulated by N-Myc via the sonic hedgehog pathway 
[115]. Finally, the cell-cycle inhibitor p15INK4b is suppressed by Myc what leads to the release 
of cell-cycle arrest mediated by the transforming growth factor-β (TGFβ) [102, 103, 116]. 
Other Myc target genes are found in specific metabolic pathways. Myc activates the 
expression of lactate dehydrogenase A (LDHA), which seems to be required for Myc-induced 
transformation of fibroblasts [117, 118]. LDHA plays a role in glucose uptake and glycolysis, 
what might explain the ‘Warburg effect’ observed with tumor cells. The ‘Warburg effect’ 
describes the observation of tumor cells showing enhanced rates of glycolysis under aerobic 
conditions [119]. Myc also leads to enhanced iron availability via the induction of the 
transferrin receptor and iron-responsive-element-binding protein-2 (IRP2) as well as the 
repression of H-ferritin and NRAMP1, which counteract the former proteins [120, 121]. 
Furthermore, Myc upregulates metabolic enzymes required for folate metabolism, which is 
important for cell growth and metabolism [122].  
Finally, Myc directly binds to promoters and activates transcription of genes 
implicated in ribosome biogenesis [123-126]. Interestingly, Myc even regulates the 
transcription of ribosomal RNA genes [127-129]. 
Other Myc targets were found in the course of differential expression screens 
comparing v-Myc transformed chicken embryonic fibroblasts (CEF) with untransformed 
CEF. Some genes were found to be enhanced after v-Myc transformation, as Osteopontin 
(OPN), which is homologous to human Secreted Phophoprotein 1 (SPP1), lipocalin Q83, 
which is possibly involved in iron metabolism and was currently found to be able to bind 
arachidonic acid, and WS5, which is meta-structurally homologous to semaphorins. Other 
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genes were repressed after v-Myc transformation including BASP1 and CRP2 (unpublished 
data). 
Those are only a few important Myc target genes. A list of putative Myc target genes 
is found at www.myccancergene.org and already comprises ~ 1700 genes. 
 
 
Myc and cellular transformation 
 
A deregulated state of myc alone is not sufficient for transformation or tumorigenesis 
and additional mutations are required for tumor formation. There are two main mechanisms 
known that limit cellular transformation by Myc. First, Myc network proteins are controlled 
post-transcriptionally by Ras-dependent signaling pathways. Second, cells have fail-safe 
mechanisms that protect them from transformation by Myc. Those mechanisms need to be 
inactivated for the cells to adopt a transformed state [130].  
For example, Myc cooperates with oncogenes from the Ras pathway to establish a 
transformed state [131-133]. Ras signaling influences the Myc network by the following 
mechanisms:  
First, Ras regulates the phosphorylation of Myc on Thr58 and Ser62 via activation of 
mitogen-activated kinases and inhibition of glycogen synthase kinase-3 (GSK3) [134-136], 
consequently stabilizing Myc. In many lymphomas, Thr58 of Myc is mutated rendering Myc 
resistant to degradation by the ubiquitin E3 ligase SCFFBW7, which recognizes phospho-Thr58 
[75].  
Second, active Ras leads – via activation of the AKT protein kinase – to the 
phosphorylation of FoxO family transcription factors, which in their non-phosphorylated state 
directly bind to and repress many Myc target genes involved in cell proliferation [137]. 
Additionally, AKT kinase phosphorylates Miz1, which is subsequently bound by 14-3-3 
proteins and released from the p21CIP1 promoter. Thereby Miz1 is no longer able to inhibit 
cell proliferation [138]. 
Third, transcriptional repression by Myc is regulated through the PI3K pathway. 
Phosphorylation at Ser71 of Myc by a Rho-dependent kinase (downstream of PI3K) leads to 
enhanced repression of thrombospondin-1 [139].  
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The Myc protein 
 
The v-myc oncogene codes for a Gag-Myc fusion protein consisting of 453 N-terminal 
residues encoded by the 5’end of the viral gag gene fused to a short stretch of six amino acids 
encoded by the 5’ untranslated region of the c-myc gene plus 416 residues encoded by the 
exons 2 and 3 of chicken c-myc [1]. Substitution mutations in the v-Myc protein compared to 
its cellular counterpart c-Myc have been found in both the N-terminal and C-terminal regions, 
which contain domains necessary for transformation.  
The N-terminus of Myc proteins harbours the transactivation domain (TAD), which is 
a major protein interaction platform, whereas the C-terminus contains the ‘basic region/helix-
loop-helix/leucine zipper’ (bHLHZip) motif, which is necessary for DNA binding, 
dimerization and protein interaction. The N-terminal TAD and C-terminal bHLHZip motif are 
connected via a suggested flexible linker region, which is less conserved between different 
species. Fig. 4 shows a schematic representation of the human c-Myc protein. 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Schematic representation of human c-Myc. TAD: transactivation domain (yellow); MB I-III: Myc 
boxes I-III (red); b: basic region (dark blue); HLH: helix-loop-helix motif (green); Zip: leucine zipper (light 
blue); NLS: nuclear localization signal (black). The extended bracket indicating TAD reminds for the recent 
finding that a C-terminally prolonged region of TAD is binding with higher affinity to interactors, than the 
previously described “minimal region” of TAD. 
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1. The bHLHZip motif of Myc 
 
The bHLHZip motif spanning residues 355 to 439 of human c-Myc comprises three 
distinct domains, which are found in other transcription factors as well. The N-terminal basic 
region (b) makes unspecific and specific contacts with the DNA phosphate backbone and 
nucleotides of the E-box sequence. The helix-loop-helix domain (HLH) and the leucine 
Zipper (Zip) with its typical heptad pattern (abcdefg)n are needed for protein dimerization. 
Information about the three-dimensional structure is provided for Mad/Max and Myc/Max 
heterodimers in complex with their cognate DNA sequence from X-ray crystallographic data 
[140]. NMR studies together with other techniques as CD spectroscopy elucidated solution 
structural and dynamic properties of monomeric v-Myc and described a beads-on-a-string 
motional behaviour of the v-Myc bHLHZip domain in solution [141]. Moreover, some X-ray 
crystal structure observations of bHLHZip proteins suggested that those proteins might be 
able to form antiparallel tetramers. Such an arrangement was for instance observed in the 
crystal structure of the c-Myc/Max/DNA complex [140] and the Max homodimer bound to its 
DNA [142]. Tetramerization of proteins of the Myc/Max/Mad network raises the possibility 
of DNA looping, which is a ubiquitously found mechanism fundamental to a lot of different 
processes including transcription, recombination and replication [143]. As a matter of fact, 
tetramers are not formed in solution and there is no evidence of specific interaction between 
two Myc/Max heterodimers. Still, at high concentrations of Myc and Max, a head-to-tail 
arrangement of Myc/Max heterodimers could be observed, which is due to dipole-dipole 
interactions between two heterodimers. The long coiled-coil structure of the Myc/Max 
bHLHZip heterodimer results in the formation of a large dipole moment due to the alignment 
of the dipoles of the individual peptide units. Binding of a Myc/Max heterodimer to DNA 
enhances dipole-dipole interaction with another DNA bound Myc/Max heterodimer, possibly 
leading to DNA looping (Bettina Schweng, doctoral thesis). Fig. 5 shows the heterodimers 
formed by the bHLHZip domains of Myc, Max and Mad bound to DNA. 
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2. The transactivation domain of Myc 
 
The N-terminal transactivation domain of Myc proteins is of special interest, as it is 
capable of binding functionally and specifically to a wide range of target proteins. Not only 
do these interactors often differ in secondary structure but also binding may result in opposing 
functions of the TAD region. The TAD harbours two highly conserved regions, Myc box I 
(MBI) and Myc box II (MBII), spanning residues 41 to 66 and 128 to 143, respectively, which 
share 80% sequence similarity with N- and L-myc [144, 145]. The Myc boxes are thought to 
be the major recognition sites for regulating proteins interacting with c-Myc. It appears, that 
most of these proteins need both Myc boxes for interaction (TRRAP, P-TEFb, NF-Y, TBP, 
Bin1, p107, Yaf2 and p21; reviewed by [64]). Recently, a third conserved region Myc box III 
(MBIII) spanning c-Myc residues 188 to 199 was described to be involved in Myc 
proteolysis. Deletion of the so-called D-element, which includes MBIII, stabilized the Myc 
protein without affecting its ubiquitylation [146]. Furthermore, MBIII is important for 
transcriptional repression and transformation by Myc. Interestingly, disruption of MBIII 
increases the efficiency of Myc to induce apoptosis [147]. Fig. 6 shows an alignment between 
c-Myc TAD of different species and v-Myc from the MC29 virus indicating the highly 
conserved Myc boxes I-III and regions with predicted secondary structural elements [145]. 
Fig. 5. Heterodimers formed by the bHLHZip domains of Myc, Max and Mad. Myc/Max (A) and Mad/Max 
(B) heterodimers bound to DNA. The basic region (b) is involved in DNA binding. The HLH and Zip 
motives are needed for dimerization. 
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Fig. 6. Alignment of v-Myc TAD and c-Myc TAD amino acid sequences from different species. The Myc boxes I-III are indicated by grey boxes. The colour code outlines 
roughly amino acid properties: acidic (blue), basic (red), hydrophobic (green), polar (yellow) as well as cysteine (orange) and proline (grey). The histogram bellow gives a 
measure of conservation between the sequences of the different species. Red boxes indicate regions, which are predicted to form amphipathic α-helices in human c-Myc 
TAD. The green box indicates a predicted α-helix. Blue boxes indicate predicted β-strands. Upper numbers correspond to human c-Myc residue numbers. 
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Former studies quoted a minimal region of Myc residues 1 to 143 being sufficient for 
transactivation in neoplastic transformation [148] and for binding to the basal transcription 
factor TBP (TATA box-binding protein) [149, 150]. Very recently studies revealed some 
information about the structure of the transactivation domain and how interaction with other 
proteins might occur. Nevertheless, very little is known about the molecular mechanisms 
leading to either transcriptional activation or repression. It was discovered that the two 
structurally and functionally orthogonal target proteins, TBP and MM1 (Myc modulator-1) 
are bound with highest specificity and affinity only by a prolonged c-Myc TAD region 
(residues 1 to 167). The additional C-terminal stretch (residues 143-167) appears to promote 
increased folding. Interestingly, already the conserved C-terminal region of human c-Myc 
TAD spanning residues 92-167 is able to bind TBP and MM1, but with less affinity. It was 
suggested, that N- and C-terminal parts of c-Myc TAD, harbouring MBI and MBII, 
respectively, act in concert during binding, possibly involving a folding-on-binding 
mechanism and a molten globule like-state [145]. 
Likewise, NMR analysis of rat B-Myc, which is most homologous to the N-terminus 
of c-Myc but being devoid of C-terminal parts, depicted a neither completely unfolded nor a 
folded protein with NOE values similar to that of molten globule proteins [151]. Interestingly, 
in the study using human c-Myc1-167 an increase in α-helical content has been observed upon 
binding to MM1 [145]. Contrary, an increase in secondary structural content was not observed 
upon interaction between rat B-Myc and MM1, although interaction was confirmed by NMR 
[151]. However, both studies describe that interaction between the respective Myc protein and 
MM1 or TBP differs in regard to specific TAD residues or domains that are used for 
interaction. Worth to notice is that MM1 is predicted to be helical and appears to hinder 
transactivation by c-Myc, while TBP, a major c-Myc target in transcriptional activation, 
consists of predominantly β-sheets [152, 153].  
These recent findings highlight the enormous potential of Myc TAD to interact with 
different proteins in a specific manner and underline the functional advantage of intrinsically 
disordered proteins. The possibility of NMR techniques to provide residue-level structural 
information even of unstructured proteins make it an indispensable tool for the investigation 
of this tantalizing class of proteins [154-157]. 
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The brain acid-soluble protein 1 (BASP1) 
 
BASP1 (brain acid-soluble protein 1, brain abundant-membrane attached signal 
protein 1) is a fascinating protein in the sense that it seems to have quite different functions. 
On the one hand it is described as a protein involved in neurite outgrowth and plamsa 
membrane organization [158-160]. On the other hand it seems to play a certain role in 
regulation of transcription [161, 162]. Finally, it belongs to the class of intrinsically 
unstructured proteins, which became of greater interest after techniques were developed, 
especially in the field of NMR, that are able to extract structural information even from quite 
disordered proteins or proteins that exist in equilibrium between folded and unfolded states.  
The homologues of human BASP1 were first identified as the brain-specific proteins 
CAP-23 (cortical cytoskeleton-associated protein of 23 kDa) in chicken brain [163] and its rat 
homologue NAP-22 (neuron-specific acidic protein of 22 kDa) [164]. Later, a group of brain 
acid soluble proteins (BASPs) were described in mammals and birds in the course of the 
search for participants in signal recognition and information transfer to the components 
controlling synaptic vesicle behaviour and neurotransmitter release in nerve endings. Four 
proteins had been identified BASP1, BASP2-1, BASP2-2 and BASP3. BASP2-1 and BASP2-
2 were confirmed as the two forms of the prominent neuronal growth-associated protein GAP-
43 (B-50, pp46, F1, neuromodulin) [165]. BASP1, despite showing a number of similar 
physico-chemical properties in common with GAP-43, belongs to a different protein family, 
the BASP1 family. Members of this protein family, as bovine BASP1, rat brain protein NAP-
22 and chicken brain protein CAP-23, show 80%, 70% and 45% sequence identity, 
respectively, to human BASP1. Several PEST sequences are found in all members of the 
BASP1 family, which are characteristic of short-living proteins. The conservation of PEST 
sequences in BASP1 of different species suggests a high significance of those sequences for 
BASP1 function [166].  
 BASP1 was identified as a myristoylated protein that is highly expressed in nerve 
terminals. It is able to bind calmodulin (CaM), despite being devoid of any canonical 
calmodulin-binding domain [167]. N-myristoylation is important not only for BASP1 binding 
to a lipid membrane but also for interaction with CaM and protein kinase C (PKC). As a 
matter of fact, BASP1 devoid of the N-terminal myristoyl moiety is not bound by CaM; 
neither is myristic acid or a short myristoylated peptide, myr-GKK. The minimal fragment 
able to bind to Ca2+-CaM with high affinity is the myristoylated nine-amino-acid N-terminal 
peptide of BASP1 (myr-G1GKLSKKKK) [168]. After co-crystallization of this peptide in 
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complex with CaM, it could be seen that the myristoyl moiety extends into a hydrophobic 
tunnel created by the hydrophobic pockets of the N- and C-terminal lobes of CaM. Moreover, 
several N-terminal residues play important roles in BASP1-CaM interaction. BASP1 Leu4 
interacts with CaM Phe12 and Met144, BASP1 Lys3 interacts with CaM Glu7 and the C-
terminal basic cluster of the myristoylated BASP1 peptide is surrounded by many acidic 
residues of CaM [169]. One mode of function of BASP1-CaM complex formation is the 
regulation of phosphorylation of BASP1 Ser5 by PKC [167]. 
At least six BASP1 immunologically related proteins (BIRPs), which represent a set of 
myristoylated BASP1 N-terminal fragments lacking C-terminal parts, have been found in 
different species. Interestingly, BASP1 proteins and BIRPs are also found in significant 
amounts in non-nervous tissues as testis, kidney and lymphoid organs (spleen, thymus), 
suggesting that they might provide different physiological functions. Interestingly, it has been 
observed, that in a definite species, the same set of BASP1 fragments is present in different 
tissues, BASP1 fragments comprising about 50% of  the total BASP1 amount in a tissue 
[170].  
A lot of studies deal with the role of BASP1 in nervous tissue. It has recently been 
shown, that overexpression of BASP1 induces neurite outgrowth in neuronal cell lines. 
Interestingly, GAP-43 could substitute for BASP1 function with respect to neural cell 
adhesion molecule (NCAM)-independent neurite outgrowth. On the contrary, NCAM-
mediated neurite outgrowth could only be stimulated by GAP-43, indicating overlapping but 
not similar roles of BASP1 and GAP-43. Mutation at the serine-5 phosphorylation site of 
BASP1 appears to have no adverse effect on this function, whereas the myristoyl moiety of 
BASP1 is indispensable for BASP1-mediated neurite outgrowth [159]. 
Other studies revealed that a myristoylated 19 amino terminal residues long fragment 
of BASP1 interacts with lipid membranes in a concentration dependent manner and is able to 
sequester PtdIns(4,5)P2 and cholesterol into lipid rafts [158, 160]. PtdIns(4,5)P2 is implicated 
in the attachment of the cytoskeleton to the plasma membrane as well as in the regulation of 
actin dynamics [171-174]. As BASP1 is able to influence the distribution of PtdIns(4,5)P2 and 
cholesterol in the membrane, it therefore might indirectly influence actin cytoskeleton 
behaviour, explaining its involvement in neuronal sprouting and plasticity. 
Considering these findings, a main function of BASP1 seems to be the regulation of 
the organization and morphology of the plasma membrane. 
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Strikingly, recent studies shed “different” light on BASP1 function, possibly being 
implicated in transcriptional regulation. BASP1 was discovered as transcriptional 
cosuppressor for the Wilms’ tumor suppressor protein 1 (WT1), which is a transcriptional 
regulator with putative target genes including those for growth factors and regulators of cell 
division. WT1 plays a key role in kidney development. Wilms’ tumor, a pediatric malignancy 
of the kidneys, has been found to either contain mutations in WT1 or aberrantly express WT1. 
BASP1 interacts with an N-terminal suppression region of WT1 (WT1 residues 92-101), 
which regulates the transcriptional activation domain. The elimination of endogenous BASP1 
expression leads to augmentation of WT1 transcriptional activation [161].  
Moreover, human BASP1 (hBASP1) was discovered in the search for apoptosis-
specific antigens. In HeLa cells hBASP1 is located in the nucleus. After induction of 
apoptosis hBASP1 is cleaved and transported into the cytoplasm in a caspase-dependent 
manner [162]. These findings, together with the identified cosuppressor activity of BASP1 on 
WT1 function, raise the possibility that the caspase-dependent change of subcellular 
localization of hBASP1 might influence the transcriptional machinery.  
Structurally, only very little is known about BASP1. As a matter of fact, 
crystallographic data exists only of the myristoylated N-terminal 19 amino acids in complex 
with CaM [169]. The meta-structure approach places BASP1 into the group of intrinsically 
unstructured proteins (IUPs), predicting very low compactness values and a low degree of 
secondary structural content (Fig. 7). Compactness values are below 200 and sometimes even 
below 0. For comparison, lowest compactness values of WT1 are around 150 and highest 
values around 600 (→ “Results” Fig. 22). This lack of secondary structure associated with 
BASP1 could also be confirmed by NMR-analysis (unpublished data). Interestingly, the meta-
structure approach further predicts a relatively small region of chicken BASP1 spanning 
residues 42 to 80 as well as human BASP1 spanning residues 42 to 90 as being highly 
probable for interaction with other proteins, presumably with an extended, loop or β-stranded 
region of a protein.  
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Fig. 7. Meta-structure analysis of chicken BASP1 yielding residue-based Compactness values and Secondary 
Structure probabilities as well as Probabilities for Protein Interaction (PPI). Ad Secondary Structure 
prediction: probabilities for α-helical segments are typically above 100 (dashed line); probabilities for 
extended conformations and β-strands are typically below 100. The region with highest probability for 
protein interaction is indicated by a red box (residues 42-80).  
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The interplay between BASP1 and Myc 
 
The list of target genes regulated by the transcription factor Myc is long, as Myc is 
implicated in a lot of different processes controlling cell behaviour. The chicken BASP1 gene 
(cBASP1) has been found to be specifically downregulated in MC29 transformed chicken 
embryonic fibroblasts (unpublished data). Current research tries to elucidate the mechanism 
how cBASP1 is regulated by Myc proteins.  
Interestingly, transformation by v-Myc is hindered by ectopic expression of cBASP1, 
suggesting that downregulation of cBASP1 is a necessary step in transformation mediated by 
v-Myc (unpublished data). It is of special interest, to solve the question how transformation 
by v-Myc is regulated by cBASP1. One possibility is that cBASP1 interacts directly with Myc 
and consequently hinders transactivation of Myc target genes. In favour of this hypothesis are 
the findings that BASP1 is able to act as a cosuppressor.  
Additionally, a small stretch of cBASP1 residues 60-80, which is predicted to be 
highly probable for protein interaction, has already been shown to lead to a cytopathic effect 
specifically in v-Myc transformed cells. 
This study tries to elucidate, if the proteins cBASP1 and v-Myc or chicken c-Myc 
interact directly. 
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Materials and Methods 
 
 
1. Microorganisms 
 
Organism Strain 
Escherichia (E.) coli DH5α 
 BL21(DE3) 
 BL21(DE3)pLysS 
 Rosetta(DE3) 
 Rosetta(DE3)pLysS 
all strains derived from novagen 
Chicken embryonic fibroblasts (CEF) 
Quail embryonic fibroblasts (QEF) 
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2. Media for Bacterial Growth 
 
LB 
Luria bertani medium 
 
 
10 g (bacto-)tryptone 
5 g yeast extract 
10 g NaCl 
(dissolve in app. 950 ml H2O, adjust pH to 7.4 with NaOH)  
H2O to a final volume of 1 l 
→ autoclave at 121°C 
→ store at 4°C 
LB 
Luria bertani medium 
    (recipe with LB-Broth) 
 
20 g LB-Broth 
→ add H2O to a final volume of 1 l 
→ autoclave at 121°C 
→ store at 4°C 
LB selective media 
LBAmp 
LBCoA 
LBKan 
 
 
1 l LB 
→ add 1 ml of ampicillin (100 mg/ml) and/or chloramphenicol 
(25 mg/ml) and/or kanamycin (25 mg/ml) just before use 
→ prepare fresh 
 
LB selective agar 
for ~ 20 plates 
 
 
500 ml LB 
7.5 g agar agar 
→ autoclave at 121°C for 15 min, cool to 55°C,  
add 500 μl of appropriate antibiotics, pour into plates 
→ store at 4°C 
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M9 medium 
 
 
6 g Na2HPO4x2H2O 
3 g KH2PO4 
0.5 g NaCl 
1 g NH4Cl 
→ dissolve in 1 l H2O, autoclave at 121°C for 15 min 
Prior to use add: 
    20 ml of 20% glucose → filtrated (0.2 µm) 
    2 ml of 1 M MgSO4 → autoclaved 
    10 ml trace elements solution → filtrated (0.2 µm) 
    0.3 ml 1 M CaCl2 → filtrated (0.2 µm) 
    antibiotics 
    optional: 1 ml biotin, 1 ml thiamine 
→ store at 4°C 
M9 medium  
for 15N-labelling of proteins 
 
s. M9 medium 
use 15NH4Cl instead of NH4Cl 
M9 medium 
for 15N, 13C-labelling of proteins 
 
s. M9 medium  
use 15NH4Cl instead of NH4Cl 
use 2 to 4 g 13C-Glucose instead of Glucose (add after 
autoclaving) 
M9 medium 
for 15N, 13C, 2H-labelling of proteins 
 
6 g Na2HPO4x2H2O 
3 g KH2PO4 
0.5 g NaCl 
1 g 15NH4Cl 
496 mg MgSO4 
2 to 4 g 13C-Glucose 
add D2O to a final volume of 1 l 
100 mg ampicillin 
12 mg Chloramphenicol 
1 mg biotin 
1 mg thiamine 
0,3 ml CaCl2 
→ sterile filtrate and use immediately 
→ use 190 mg IPTG for induction of protein expression 
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TY 2x 
 
 
16 g (bacto-) tryptone 
10 g yeast extract 
5 g NaCl 
H2O to a final volume of 1 l 
→ autoclave at 121°C for 15 min 
→ store at 4°C 
 
 
 
 
3. Buffers and Solutions 
 
Acrylamide/bisacrylamide 
(separation gel) 
33 % (w/v) acrylamide 
0.9 % (w/v) bisacrylamide 
 
 
33 g acrylamide 
0.9 g bisacrylamide (N,N’-methylene bisacrylamide) 
H2O to a final volume of 100 ml 
→ sterilize by filtration (0.2 µm) 
→ store light-protected at 4°C 
Acrylamide/bisacrylamide 
(stacking gel)  
20 % (w/v) acrylamide 
1 % (w/v) bisacrylamide 
 
 
20 g acrylamide 
1 g bisacrylamide (N,N’-methylene bisacrylamide) 
H2O to a final volume of 100 ml 
→ sterilize by filtration (0.2 µm) 
→ store light-protected at 4°C 
Ammoniumperoxodisulfate 
(APS) 
10 % (w/v) 
 
 
1 g ammoniumperoxodisulfate 
H2O to a final volume of 10 ml 
→ store at -20°C 
Ampicil l in 
100 mg/ml (≅0.27 M) 
     
 
1 g ampicillin 
H2O to a final volume of 10 ml 
→ sterilize by filtration (0.2 µm) 
→ store at -20°C 
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AP buffer 
100 mM Tris×HCl (pH 9.5) 
100 mM NaCl 
5 mM MgCl2 
 
6.06 g tris base 
2.92 g NaCl 
0.51 g MgCl2×6H2O  
→ dissolve in H2O 
→ adjust to desired pH 
H2O to a final volume of 500 ml 
Blocking solution 
10 mM NaxH(3-x)PO4 (pH 7.4) 
150 mM NaCl 
0.1 % v/v Tween 20 
5 % w/v non fat dry milk 
 
 
5 g non fat dry milk 
PBS-T buffer to a final volume of 100 ml 
→ make fresh before use 
Bradford reagent 
 
 
1 ml ethanol abs. 
2 ml H3PO4 
21 ml H2O 
1ml Serva Blue G solution 
→ let stand for 30 min at room temperature before 
use  
Bromphenol blue 
0.5% 
 
5 mg bromphenol blue 
H2O to a final volume of 1 ml 
BSA solution  
1 mg/ml 
     
 
10 mg bovine serum albumin 
H2O to a final volume of 10 ml 
→ store at -20°C 
CaCl2  
1 M 
     
 
14.7 g CaCl2×2H2O  
H2O to a final volume of 100 ml  
→ autoclave at 121°C for 15 min 
Chloramphenicol 
25 mg/ml 
     
 
250 mg chloramphenicol 
EtOH to a final volume of 10 ml 
→ store at -20°C 
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Coomassie staining solution 
0.5% (w/v) Coomassie 
50% (v/v) EtOH 
10% (v/v) HOAc 
 
 
2.5 g Coomassie Brilliant Blue R-250 
250 ml EtOH (98%) 
50 ml HOAc (99%) 
H2O to a final volume of 500 ml 
→ store light protected 
Destaining solution 
for protein gels 
30% (v/v) EtOH 
10% (v/v) HOAc 
 
 
300 ml EtOH (98%) 
100 ml HOAc. (99%) 
H2O to a final volume of 1 l  
Dialysis buffer  
20 mM Tris×HCl (pH 7.4) 
1 mM EDTA 
1mM β-Mercaptoethanol 
4 M Urea 
 
2.42 g tris base (121.14 g/mol) 
1ml 1 M EDTA pH 8.0 
144µl β-Mercaptoethanol 
240.24 g Urea (60.06 g/mol) 
→ dissolve in H2O (!! volume !!) 
→ adjust to desired pH (with HClconc) 
H2O to a final volume of 1 l 
Dithiothreitol (DTT)  
1 M 
 
 
1.54 g dithiothreitol 
H2O to a final volume of 10 ml 
→ sterilize by filtration (0.2 µm) 
→ store at -20°C 
DNA sample buffer (5x) 
for agarose gel electrophoresis 
20 mM EDTA 
30 % (w/v) Glycerine 
0.5 % (w/v) SDS 
0.1 % (w/v) Bromphenol blue 
 
 
100 µl EDTA 1 M (pH 8.0) 
5 mg bromphenol blue 
1.7 ml glycerine 
125 µl SDS 20 % 
H2O to a final volume of 5 ml 
→ store at 4°C 
dNTP Mix (2mM each) 
2 mM dATP 
2 mM dCTP 
2 mM dGTP 
2 mM dTTP 
 
 
10 µl dATP 100 mM 
10 µl dCTP 100 mM 
10 µl dGTP 100 mM 
10 µl dTTP 100 mM 
H2O to a final volume of 500 µl 
→ aliquote and store at -20°C 
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EDTA buffer  
1 M EDTA pH 8.0 
 
 
186.1 g Titriplex III (372.2 g/mol) 
20 g NaOH 
H2O to a volume of about 400 ml 
→ adjust pH with 5 M NaOH  
H2O to a final volume of 500 ml  
→ autoclave at 121°C for 15 min 
Ethidium bromide 
10 mg/ml 
 
 
(BioRad)  
→ store light protected at 4°C 
Glucose  
1 M 
 
 
19.8 g Glc×H2O  
H2O to a final volume of 100 ml  
→ sterilize by filtration (0.2 µm) 
→ store at 4°C 
HCl  
1 M 
 
 
50 ml HClconc (32 %, ρ=1.16)  
H2O to a final volume of 500 ml 
High imidazole buffer 
20 mM Tris×HCl (pH 7.4) 
0.5 M Imidazole 
 
 
2.42 g tris base 
17.02 g imidazole (68.08 g/mol) 
→ dissolve in H2O 
→ adjust pH 
H2O to a final volume of 0.5 l 
Inclusion bodies washing buffer 
( IBW) 
50 mM Tris×HCl pH 8.0 
2 mM EDTA 
5% (v/v) Glycerine 
1% (v/v) Triton X-100 
(1 mM DTT or 1 mM β-Mercaptoethanol) 
 
 
25 ml Tris×HCl 1 M (pH 8.0) 
1 ml EDTA 1 M (pH 8.0) 
25 ml 100% glycerine 
5 ml Trition X-100 
H2O to a final volume of 500 ml  
optional: add prior to use: DTT or β-Mercaptoethanol 
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IPTG  
1 M 
 
2.4 g IPTG (238.25 g/mol) 
H2O to a final volume of 10 ml  
→ sterilize by filtration (0.2 µm) 
→ store at -20°C 
 
Kanamycin 
25 mg/ml 
 
 
250 mg Kanamycin monosulfate 
H2O to a final volume of 10 ml 
→ sterilize by filtration (0.2 µm) 
→ store at -20°C 
KCl  
1 M 
 
 
7.46 g KCl (74.55 g/mol) 
H2O to a final volume of 100 ml 
→ autoclave at 121°C for 15 min  
K2HPO4 
50 mM 
 
11.4 g K2HPO4×3H2O  (228.23 g/mol) 
H2O to a final volume of 1 l 
KH2PO4 
50 mM 
 
6.8 g KH2PO4  (136.09 g/mol) 
H2O to a final volume of 1 l 
KOAc buffer pH 6.0 
3 M 
 
29.45 g KOAc (98.15 g/mol) 
H2O to a volume of about 90 ml 
→ adjust pH (with HOAc)  
H2O to a final volume of 100 ml  
Laemmli buffer                    
(Tr is -g lyc ine e lec trophores is  buf fer )  
25 mM Tris 
190 mM Glycine 
0.1 % SDS 
 
 
6 g tris base 
28.75 g glycine  
2 g SDS  
H2O to a final volume of 2 l 
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Low imidazole buffer 
20 mM Tris×HCl (pH 7.4) 
10 mM Imidazole 
 
 
2.42 g tris base 
0.68 g imidazole (68.08 g/mol) 
→ dissolve in H2O 
→ adjust pH 
H2O to a final volume of 1 l 
Lysis buffer  
    ’NaPi  NaCl pH 7.4’  
20 mM NaxH(3-x)PO4 (pH 7.4) 
100 mM NaCl 
1 mM EDTA 
1 mM β-Mercaptoethanol 
 
 
 
5.48 g NaCl 
1 ml 1 M EDTA pH 8.0 
144 µl β-Mercaptoethanol 
NaP buffer to a final volume of 1 l 
Lysis buffer  
    ’Tris pH 7.4’ 
20 mM Tris×HCl (pH 7.4) 
1 mM EDTA 
1 mM β-Mercaptoethanol 
 
 
2.42 g tris base 
1 ml 1 M EDTA pH 8.0 
144 µl β-Mercaptoethanol 
H2O to a final volume of 1 l 
MgCl2  
1 M 
 
20.33 g MgCl2×6H2O  
H2O to a final volume of 100 ml 
→ autoclave at 121°C for 15 min 
MgSO4  
1 M 
 
24.78 g MgSO4×7H2O (246.48 g/mol) 
H2O to a final volume of 50 ml 
→ autoclave at 121°C for 15 min 
MnCl2   
1 M 
 
3.96 g MnCl2×4H2O  
H2O to a final volume of 20 ml 
→ sterilize by filtration (0.2 µm) 
→ store at -20°C 
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MOPS buffer  
1 M pH 7.0 
 
 
20.93 g MOPS 
→ dissolve in H2O 
adjust pH with NaOH 
H2O to a final volume of 100 ml 
→ sterilize by filtration (0.2 µm) 
→ store at -20°C 
Na2HPO4  
20 mM 
 
 
3.55 g Na2HPO4×2H2O (177.99 g/mol) 
H2O to a final volume of 1 l 
NaH2PO4  
20 mM 
 
 
2.76 g Na2HPO4×H2O (137.99 g/mol) 
H2O to a final volume of 1 l 
NaCl  
2 M 
 
58.44 g NaCl  
H2O to a final volume of 500 ml 
→ autoclave at 121°C for 15 min 
NaOAc buffer 
for DNA precipitation 
3 M 
 
24.6 g NaOAc  
H2O ad about 80 ml  
adjust to desired pH with HOAc 
H2O to a final volume of 100 ml 
→ autoclave at 121°C for 15 min 
NaOH 
1 M 
 
 
20.00 g NaOH 
H2O to a final volume of 500 ml 
NaP buffer 
20 mM sodium phosphate pH 7.4 
 
adjust pH by mixing  
    20 mM NaH2PO4 100 mM NaCl  
    20 mM Na2HPO4 100 mM NaCl  
    to a final volume of 1 l 
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PBS buffer 
10 mM NaxH(3-x)PO4 (pH 7.4) 
150 mM NaCl 
 
 
10 ml 1 M NaxH(3-x)PO4 (pH 7.4) 
75 ml 2 M NaCl  
→ dissolve in H2O 
→ adjust pH with NaOH 
H2O to a final volume of 1 l 
→ autoclave at 121°C for 15 min 
PBS-T buffer 
10 mM NaxH(3-x)PO4 (pH 7.4) 
150 mM NaCl 
0.1 % v/v Tween 20 
 
 
1 ml Tween 20 
PBS buffer to a final volume of 1 l 
→ autoclave at 121°C for 15 min 
Ponceau-S staining solution 
0.1 % Ponceau S 
5 % acetic acid  
 
 
(Sigma Aldrich) 
2x Protein sample buffer         
(SDS-PAGE) 
120 mM Tris×HCl, pH 6.8 
6 % (w/v) SDS 
20 % (v/v) Glycerine 
0.01 % (w/v) Bromphenol blue 
10 % (v/v) β-Mercaptoethanol 
 
 
1.2 ml Tris×HCl 1 M (pH 6.8) 
3 ml SDS 20 % 
2 ml glycerine 
1 mg Bromphenol blue 
H2O to a final volume of 9 ml  
→ store in 900µl aliquots at -20°C 
→ thaw only once 
Add 100 µl of β-mercaptoethanol to 900 µl of buffer  
→ store at 4°C 
RbCl  
4 M 
 
9.67 g RbCl  
H2O to a final volume of 20 ml  
→ sterilize by filtration (0.2 µm) 
SDS 20% 
20% SDS (w/v) 
 
20 g SDS 
H2O to a final volume of 100 ml  
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Stop Mix (5x) 
for DNA restriction 
20 mM EDTA 
30 % Glycerine 
0.5 % SDS 
0.1 % bromphenol blue 
 
0.1 ml 1 M EDTA (pH 8.0) 
1.7 ml glycerine 
0.125 ml 20 % SDS 
2 ml 0.5% bromphenol blue 
H2O to a final volume of 5 ml 
 
Stripping buffer 
20 mM Tris×HCl (pH 7.4) 
10 mM Imidazole 
1 M NaCl 
50 mM EDTA 
 
 
2.92 g NaCl 
5 ml 0.5 M EDTA 
Low imidazole buffer to a final volume of 50 ml 
TBE buffer (10×)  
pHcalc 8.3 
0.89 M Tris 
0.89 M Boric acid  
0.02 M EDTA 
 
 
108 g tris base 
55 g H3BO3  
7.44 g EDTA Na2×2H2O  
H2O to a final volume of 1 l  
→ autoclave at 121°C for 15 min 
TE buffer  
20 mM Tris×HCl (pH 7.4) 
1 mM EDTA 
 
2.42 g tris base 
1 ml 1 M EDTA pH 8.0 
→ dissolve in H2O 
→ adjust to desired pH (with HClconc) 
H2O to a final volume of 1 l 
TEU buffer  
20 mM Tris×HCl (pH 7.4) 
1 mM EDTA 
7 M Urea 
 
2.42 g tris base 
1ml 1 M EDTA pH 8.0 
420.42 g Urea (60.06 g/mol) 
→ dissolve in H2O (!! volume !!) 
→ adjust to desired pH (with HClconc) 
H2O to a final volume of 1 l 
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TEUS buffer  
20 mM Tris×HCl (pH 7.4) 
1 mM EDTA 
7 M Urea 
1 M NaCl 
 
2.42 g tris base 
1ml 1 M EDTA pH 8.0 
420.42 g Urea (60.06 g/mol) 
58.44 g NaCl (58.44 g/mol) 
→ dissolve in H2O (!! volume !!) 
→ adjust to desired pH (with HClconc) 
H2O to a final volume of 1 l 
TFB I I  solution  
10 mM MOPS, pH 7.0 
75 mM CaCl2 
10 mM NaCl 
15 % (v/v) Glycerine 
 
 
50 µl MOPS 1 M (pH 7.0) 
375 µl CaCl2 1 M 
25 µl NaCl 2 M 
0.75 ml glycerine 
H2O to a final volume of 5 ml 
→ prepare fresh 
→ sterilize by filtration (0.2 µm) 
TFB I  solution  
100 mM RbCl 
50 mM MnCl2 
10 mM CaCl2 
30 mM KOAc pH 6.0 
15 % (v/v) Glycerine 
 
1.25 ml RbCl 4 M 
2.50 ml MnCl2 1 M 
0.50 ml CaCl2 1 M 
0.50 ml KOAc 3 M (pH 6.0) 
7.50 ml glycerine 
H2O to a final volume of 50 ml   
→ prepare fresh 
→ sterilize by filtration (0.2 µm) 
10x Transfer buffer          
(without Methanol) 
tris base 
glycine 
 
 
30 g tris base 
144 g glycine 
H2O to a final volume of 800 ml  
Transfer buffer 
tris base 
glycine 
20 % v/v methanol 
 
 
100 ml 10x Transfer buffer (without methanol) 
200 ml methanol 
H2O to a final volume of 1 l  
Urea 
8 M 
 
6 g Urea 
H2O to a final volume of 100 ml 
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4. General Methods:   DNA 
 
4.1. Agarose Gel Electrophoresis of DNA 
 
A DNA fragment migrates at different rates through gels containing different 
concentrations of agarose. By varying agarose concentration, it is possible to resolve a wide 
range of DNA fragments. 
 
agarose concentration 
% (w/v) 
range of separation 
(bp) 
agarose for 10 ml gel 
(g) 
agarose for 30 ml gel 
(g) 
0.3 5000 – 60000 0.03 0.09 
0.6 1000 – 20000 0.06 0.18 
0.7 800 – 10000 0.07 0.21 
0.9 500 – 7000 0.09 0.27 
1.2 400 – 6000 0.12 0.36 
1.5 200 – 3000 0.15 0.45 
2.0 100 – 2000 0.20 0.60 
3.0 50 - 1000 0.30 0.90 
 
• Add the appropriate amount of agarose to an appropriate amount of 1xTBE buffer. 
→ For high percentage gels (3-5%) add an excess amount of distilled H2O to 
increase the weight by 10-20% (or preferentially use a vertical polyacrylamide 
gel for tiny fragments). 
• Heat the suspension in the microwave to the boiling point. 
→ For high percentage gels (3-5%): check (by weighing) that the excess 10-20% 
of water has evaporated and, if needed, continue boiling to remove the excess 
water, or add hot distilled water to restore the initial weight. 
• Cool to ~ 50°C in a water bath, add 1 µl of Sybr-Safe 1:1000 dilution (invitrogen) per 10 
ml of gel. 
• Pour agarose into a prepared gel tray with a comb. 
• Let the gel polymerize at room temperature (protect from light, when using Sybr-Safe). 
• Put the gel in a horizontal gel chamber, fill with 1xTBE and remove the comb. 
• Load DNA sample dissolved in DNA sample buffer, run gel at 40-60 V for 1 hr or 90-
100 V for 30 min. 
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• Detect bands with the help of a UV-transilluminator. 
• Elute DNA from gels using the QIAEXII Gel Extraction Kit (Qiagen). 
 
 
4.2. Cloning of DNA fragments 
 
4.2.1. Digestion of DNA with restriction endonucleases 
 
Depending on subsequent experiments, an appropriate amount of DNA has to be 
digested. For analytical purposes (verification of constructs by restriction digest) only minor 
amounts of DNA may be used. (Typically, a band is easily visible, if it contains about 20 ng 
of DNA. The detection limit for SYBR Safe stain as well as ethidium bromide is roughly 0.5 
ng/band in a minigel for fragments larger than 200 bp viewed on a 300 nm transilluminator).  
If follow-up experiments include gel extraction of specific bands, purification of DNA 
fragments and ligation, the amount of DNA used for digestion has to be adapted to a minimal 
amount, which will be needed for ligation, bearing in mind, that DNA might be lost during 
successive experimental steps.  
By definition, 1 unit of restriction enzyme will completely digest 1 µg of substrate 
DNA in a 50 µl reaction in 60 minutes.  
 
 
e.g.: for analytical purpose 
Vfinal = 10 µl 
DNA (plasmid or PCR product) 0.5-3 µg 5 µl (~ 0.1 µg/µl) 
10x restriction buffer  1 µl 
10x BSA (optional)  1 µl 
H2O to appropriate volume 2.5 µl 
Restriction enzyme 5-10 U 0.5 µl (10 U/µl) 
 
→ Incubate at the recommended temperature for 2 hrs (up to o/n). With some enzymes star 
activity has been observed, i.e. time of digestion must not be too long. 
→ If necessary terminate the reaction by incubation of the solution at the inactivation 
temperature for 10 to 20 min or by adding 1/4 of the total volume of 5x DNA sample buffer. 
→ Store at 4°C or directly load onto a gel. 
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Additional information: 
• The volume of the enzyme added must not exceed more than 10% of the total volume, as 
the glycerine within the enzyme buffer may inhibit restriction. 
• If the DNA has to be cleaved with two restriction enzymes or modified with other 
enzymes e.g. alkaline phosphatase or blunt ending enzymes, the reactions can be carried 
out simultaneously if both enzymes are active in the same buffer. Alternatively, the 
enzyme with the buffer of lower ionic strength should be used first. The appropriate 
amount of salt and the second enzyme can be added subsequently. Another way is to 
precipitate DNA after the first digestion and then perform the second one. 
 
 
4.2.2. Phosphatase treatment of DNA fragments 
 
Alkaline Phosphatases (AP) catalyze the removal of 5’ phosphate groups from DNA, 
RNA, ribo- and deoxyribonucleoside triphosphates. They can even remove phosphate groups 
from proteins. There are different sources of alkaline phosphatase. Most widely used is calf 
intestinal alkaline phosphatase (CIP), which can be inactivated by heat. One application of 
alkaline phosphatase in nucleic acid manipulation is the removal of 5’ phosphates from 
plasmid or bacteriophage vectors that have been cut with restriction enzymes. This prevents 
religation of vectors, if only one restriction enzyme was used, and insertion of unwanted DNA 
fragments, if two restriction enzymes were used, respectively. As alkaline phosphatases are 
very active, they have to be either inactivated or quantitatively removed before proceeding to 
subsequent experiments (e.g.: ligation). 
 
1 µl of CIP was added directly to the digestion mixture (35 µl) and incubated for ~ 1 h 
at 37°C. The reaction mixture was subsequently purified using a PCR purification kit 
(Qiagen) to remove enzymes and other contaminants. The digested and CIP-treated vector 
DNA was dissolved in H2O. 
 
Additional information: 
• The DNA fragment, which is inserted into the vector, is NOT to be treated with 
phosphatase. 
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4.2.3. Ligation of DNA fragments 
 
Depending on the ligation conditions (sticky end or blunt end ligation, CIP-treatment 
of vector DNA, etc.) the insert:vector molar ratio may be differently chosen (3:1, 1:1, 1:3). 
Usually 100ng of vector DNA in a final volume of 10-20 µl is used in a standard ligation 
protocol. 
 
Molar Ratio of Insert to Vector: 
 
 
       
 
 
 
e.g.: molar ratio insert:vector = 3:1 
Vfinal = 20µl 
insert → 737 bp 
vector → 5350 bp 
Vector DNA 100ng 5 µl (20 ng/µl) 
Insert DNA according to molar ratio 3 µl (14 ng/µl) 
5x  T4 DNA Ligase buffer  4 µl 
H2O to appropriate volume 6.8 µl 
T4 DNA Ligase 0.1-1.0 U  0.2 µl (5U/µl) 
 
→ Incubate at 16°C o/n. 
→ Inactivate DNA Ligase at 65°C for 10 min or directly transform bacteria with ligation mix. 
 
 
 
 
 
 
 
 
 
( )
( )      ×=
length of insert in kb
ng of vectorng of insert needed for a 1: 1 ratio        
length of vector in kb
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4.2.4. Polymerase Chain Reaction (PCR) 
 
 
Standard PCR mixture 
 e.g.: Vfinal = 20µl 
Vector DNA  1-50 ng 0.25 µl (0.2 µg/µl) 
10x Taq Pol buffer (MgCl2 free)   2 µl 
MgCl2 50mM  1-6 mM 1.2 µl (≙ 3mM) 
dNTP mix (2mM each)  0.2 mM 2 µl 
forward primer 10µM  10-50 pmol 1 µl (≙ 10 pmol) 
reverse primer 10µM 10-50 pmol 1 µl (≙ 10 pmol) 
H2O to appropriate volume 12.35 µl 
T4 Taq polymerase (1U/µl) 0.2 U 0.2 µl 
 
 
 
Standard PCR program 
 e.g.: for ~100bp PCR product 
denaturation/activation 95°C 00:05:00 95°C 00:05:00 
 
30x 
denaturation 95°C 00:00:30 95°C 00:00:20 
annealing 55 – 65°C 00:00:30 53°C / 56°C / 60°C 00:00:20 
elongation 72°C 20 sec – 3 min 72°C 00:00:20 
final elongation 72°C 00:05:00 72°C 00:05:00 
 4°C hold 4°C hold 
 
 
• Either add the appropriate amount of DNA sample buffer (5x) and purify PCR product 
by agarose gel electrophoresis using low melting agarose (BIORAD) and the QIAEXII 
Gel Extraction Kit (Qiagen) or purify it via PCR purification kit (Qiagen) without 
running a gel. 
• Very small PCR-products are purified by phenol:chloroform extraction and subsequent 
iso-propanol precipitation. 
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4.2.5. Preparation of competent bacteria (Hanahan) [175] 
 
• Prepare an overnight culture of the respective E. coli strain; inoculate LB medium 
supplemented with the appropriate antibiotics with cells from the bacterial stock 
solution. 
• Inoculate 100 ml of 2x TY medium with 1 ml of the overnight culture. 
• Let the bacteria grow at 37°C and 225 rpm until an OD600 = 0.4-0.5. 
• Cool the flask for 10-15 min on ice. 
• Pour the culture into ice-cold 50 ml conical tubes. 
• Centrifuge at 4°C for 10 min at 4000 x g and discard the supernatant. 
• Resuspend gently the pellet in 100 ml ice-cold TFB I solution. 
• Incubate on ice for 10 min. 
• Centrifuge as above and discard supernatant. 
• Resuspend the pellet in 4 ml of ice-cold TFB II solution. 
• Immediately prepare 100 μl aliquots in pre-chilled 2 ml tubes and store them at –80°C 
• Recommended: test the transformation efficiency by transforming 10 ng of pUC19 
plasmid DNA according to the heat-shock protocol. The efficiency should be about 
1x106 to 1x107 pfu per μg of DNA. 
 
 
4.2.6. Transformation of E. coli bacteria – heat shock protocol 
 
• Thaw a 100 µl aliquot of competent cells on ice. 
• Add ~ 10 ng of plasmid DNA and incubate the mixture on ice for 2-30 min. 
• Incubate the mixture at 42°C in a water bath for 90 sec. 
• Cool 2 min on ice. 
• Add 300 µl of LB medium and incubate at 37°C for 45 min at 225 rpm. 
• Plate 50 to 400 µl of bacterial suspension on an agar plate containing the appropriate 
antibiotics. 
• Place the plate in an incubator at 37°C for 10 to 15 hrs. 
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4.2.7. Preparation of E. coli starter cultures  
 
 
Starter cultures for plasmid midi preparations 
  
• Inoculate 50-100 ml of LB medium supplemented with the appropriate antibiotics with a 
single colony from a transformation plate using a sterile pipette tip. Alternatively, use 1 
µl of a glycerol stock for inoculation. 
• Incubate at 37°C and 225 rpm for at least 12 hrs. 
 
Starter cultures for recombinant protein expression 
 
• inoculate 20 ml of LB medium (optional: supplemented with 2 g/l glucose to prevent 
that galactose from the medium induces the IPTG system) containing the appropriate 
antibiotics with one or more colonies from a transformation plate 
• incubate at 37°C and 225 rpm over night (or until OD600 reaches 1.0 to 1.5) 
 
 
 
4.2.8. Preparation of plasmid DNA from bacteria 
 
• Plasmid DNA from bacteria was obtained using Plasmid Mini or Midi Kits (Qiagen) 
according to the manufacturer’s instructions. 
 
 
 
4.2.9. Phenol:Chloroform extraction of DNA 
 
Phenol:chloroform extraction is a way to remove proteins from nucleic acid solutions. 
A subsequent extraction with chloroform is performed to remove traces of phenol. 
 
• The phenol has to be adequately equilibrated to a pH of 7.8-8.0. 
• Add H2O to the DNA solution to a final volume of 200 µl. 
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1. Add an equal volume of phenol:chloroform. 
2. Mix until an emulsion forms → vortexing is possible when isolating small DNA 
molecules (<10 kb). 
3. Centrifuge at maximum speed in a table-top centrifuge for 1 min at room temperature. 
 → organic and aqueous phase should be separated. 
4. Transfer the aqueous phase to a fresh tube and discard interface and organic phase.  
 → optional: interface and organic phase may be “back-extracted”. 
 
• Repeat steps 1-4 until no protein is visible at the interface. 
• Add an equal volume of chloroform and repeat steps 2-4. 
• Recover the nucleic acid by EtOH or iso-propanol precipitation. 
 
 
4.2.10. EtOH precipitation of DNA 
 
• Start with a total volume of 100 to 200 µl of DNA solution, pre-chill on ice. 
• Add 1/10 of the total volume of 3 M NaOAc (pH 5.2). 
• Add 2.5 volumes of ice cold EtOHabs, mix and incubate at –20°C for 30 min. 
• Centrifuge at 4°C for 30 min at 13000 rpm. 
• Wash the pellet with 150 µl of ice cold 70% EtOH, centrifuge briefly. 
• Discard supernatant and air-dry the pellet (or dry carefully with a Speed Vac). 
 
 
4.2.11. iso-Propanol precipitation of DNA 
 
• Add 1/10 of the total volume of 3 M NaOAc (pH 5.2) to the DNA solution. 
• Add 1 volume of iso-propanol, mix and incubate at –20 °C o/n. 
• Centrifuge at 4°C for 30 min at 13000 rpm. 
• Wash the pellet with 150 µl of ice cold 70% EtOH, centrifuge briefly. 
• Discard supernatant and air-dry the pellet (or dry carefully with a Speed Vac). 
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4.2.12. Quantification of nucleic acids 
 
• Prepare 100 µl dilutions of DNA in H2O in concentrations of about 5 to 50 μg/ml. 
• Measure the absorbance at 260 and 280 nm in a UV Spectrophotometer. 
• The following assessments can be used for quantification: 
   DNA: A260 = 1 at a concentration of 50 μg/ml 
   RNA: A260 = 1 at a concentration of 40 μg/ml 
• A ratio of A260/A280 between 1.6 and 2.0 indicates pure DNA or RNA without significant 
protein contamination. 
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5. General methods:   Protein 
 
 
5.1. Expression of recombinant proteins 
 
• Plasmid DNA from bacteria was obtained using Plasmid Mini or Midi Kits (Qiagen). 
• Transform the respective E. coli strain with the expression plasmid containing the gene 
sequences of the protein of interest (→ section 4.2.6: “Transformation of E. coli bacteria 
– heat shock protocol”). 
• Prepare a starter culture in LB medium as described. 
• When the starter culture has reached optimal OD600 dilute 1/10 to 1/30 with expression 
medium containing the appropriate antibiotics. 
• Incubate at 20 to 37°C and 225 rpm until OD600 reaches 0.5 to 0.9 (depending on the 
protein to be expressed). 
• Control 1: Pipet 1 ml of the culture into an 1.5 ml tube, centrifuge at 4000 rpm for 5 
min, remove the supernatant and suspend the pellet in 50 µl of 1x protein sample buffer, 
store at –20°C. 
• Induce protein expression by adding IPTG. Exact conditions for induction and further 
incubation depend on the nature of the expressed protein; final IPTG concentration 
ranges from 0.4 to 2 mM, incubation temperature and time range between 37°C for 
several hours and 18°C over night. 
• Control 2: Measure OD600 of the culture. Pipet 1 ml of the culture into a 1.5 ml tube and 
centrifuge at 4000 rpm for 5 min. Remove the supernatant and resuspend the pellet in 
200 µl of lysis buffer and lyse the cells, e.g. by sonication. Take a sample and mix 1:1 
with 2x protein sample buffer. Centrifuge at 18000 rpm for 10 min, take a sample from 
the supernatant and mix 1:1 with 2x protein sample buffer. Store the samples at –20°C. 
 
 
 
 
 
 
 
 55 
Harvesting: 
 
• Cool the flask with the expression culture for 15 min on ice. 
• Centrifuge for 15 min at 4000 rpm at 4°C. 
• Remove the supernatant and dissolve the pellet in 30 ml of ice-cold lysis buffer per liter 
of bacterial culture. The optimal buffer conditions depend on the properties of the 
protein of interest and have to be optimized for every purification. E.g. use Tris×HCl 
buffer for acidic proteins (purified by anion exchange chromatography), or a sodium 
phosphate buffer for basic proteins (purified by cation exchange chromatography). Lysis 
buffers can also contain various amounts of salt (10 to 500 mM), reductants as 0.1% 
(w/v) β-mercaptoethanol or 0.5 to 10 mM DTT, and metal ions if the protein is a metal 
binding protein. 
• Freeze the bacterial suspension in liquid nitrogen and store at –20°C o/n or –80°C for 
long term storage. 
• Check the expression of the recombinant protein using SDS-PAGE. Load 10 to 20 μl of 
the control samples and compare the amount of insoluble and soluble protein fraction. 
 
 
5.2. Preparation of lysates for protein purification 
 
• Thaw the bacterial suspension on ice or in a room tempered water bath. 
• If the recombinant protein is expressed in pLysS strains incubate the suspension on ice 
for 1 hr. These strains contain lysozyme and will lyse during thawing. 
• Sonicate the lysate for 10 min on ice (sonicator-conditions: sonicator tip should reach at 
least 5mm beneath the surface; 40-60% power; 30-50% of a second pulse-length). This 
breaks the cells and fragments the bacterial DNA. 
• Centrifuge the lysate at 4°C and 18000 rpm for 15-30 min. This should result in a 
compact pellet and a clear supernatant. 
• If not previously done, analyze aliquots of the supernatant and the pellet (soluble vs. 
insoluble protein fractions) equivalent to 50 µl of bacterial culture by SDS-PAGE. 
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5.3. Enrichment of inclusion bodies 
 
If a recombinant protein is expressed in inclusion bodies this has both, advantages 
and disadvantages. As an advantage, inclusion bodies are mostly free of other components, so 
they can be treated as almost pure protein. However, inclusion bodies are insoluble and the 
protein has to be denatured and refolded to obtain viable samples. Anyway, the inclusion 
bodies have to be washed to get rid of cell fragments and other remainders of bacterial cells, 
and afterwards a special denaturing/renaturing protocol has to be established for each 
protein. 
 
• After lysis resuspend the pellet (from 1 l expression culture) in 3.5 ml IBW buffer.  
 → sonicate briefly to destroy cell clumps and for resuspension. 
• Centrifuge at 4°C and 18000 rpm for 10-15 min. 
• Discard supernatant and resuspend the pellet in 3.5 ml of IBW buffer.  
 → sonicate briefly to destroy cell clumps and for resuspension. 
• Centrifuge at 4°C and 18000 rpm for 10-15 min. 
• Discard supernatant and resuspend the pellet in 3.5 ml of NaP buffer.  
 → sonicate briefly to destroy cell clumps and for resuspension. 
• Centrifuge at 4°C and 18000 rpm for 10-15 min. 
• Discard supernatant and solubilize the pellet in a suitable buffer for subsequent 
purification steps (e.g. 8 M Urea or TEU buffer). 
 
 
5.4. Refolding of proteins using stepwise dialysis 
 
• Dissolve the pellet in an appropriate denaturing agent, e.g. 8M Urea or TEU buffer. 
 → to dissolve the protein more easily,  the suspension can be heated to 37°C. 
• Centrifuge at 4°C and 18000 rpm for 10 min to remove insoluble particles. 
• Equilibrate a dialysis bag with a cut off value smaller than the molecular weight of the 
protein in about 50 ml of dialysis buffer or water. 
• Fill the denatured protein sample in the dialysis bag and close with clamps. 
• Dialyze into 200 ml of dialysis buffer (target buffer + 4M Urea) at 4°C for 30 to 40 min 
under stirring. 
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• Add 66 ml of target buffer to give a final concentration of 3 M Urea.  
 → Continue dialysis at 4°C for 30 to 40 min. 
• Add 132 ml of target buffer to give a final concentration of 2 M Urea.  
 → Continue dialysis at 4°C for 30 to 40 min. 
• Add 400 ml of target buffer to give a final concentration of 1 M Urea.  
 → Continue dialysis at 4°C for 30 to 40 min. 
• Add 800 ml of target buffer to give a final concentration of 0.5 M Urea.  
 → Continue dialysis at 4°C for 30 to 40 min. 
• Dialyze into 1000 ml target buffer over night at 4 °C. 
 
 
 
 
5.5. Concentration of protein samples using membrane 
filters 
 
Centriprep or Centricon filters (Amicon) are suitable to generate highly concentrated 
protein samples, e.g. to obtain protein samples of high concentration for NMR analysis under 
native conditions. 
 
• Transfer the protein solution to a centriprep (up to 15 ml volume) or a centricon (up to 2 
ml volume) with a cut off value smaller than the molecular weight of the protein. 
• Centrifuge at 4000 rpm at 4°C; the buffer will pass the filter, while the protein will be 
retained. 
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5.6. Chromatographic Methods 
 
 
 
5.6.1. The Fast Performance Liquid Chromatography (FPLC) 
System 
 
Protein purification was performed using the FPLC system Äktaexplorer from 
amersham pharmacia biotech. Chromatographic methods used were affinity, ion exchange 
and size exclusion chromatography. All FPLC purification steps were performed either at 
room temperature or at 4°C. 
 
 
 
5.6.2. Immobilized metal ion affinity chromatography IMAC (HiTrap 
Chelating HP 5ml) 
 
HiTrap Chelating HP 5ml is a pre-packed column from amersham pharmacia. The 
matrix is composed of iminodiacetic acid coupled via a spacer arm of seven atoms to highly 
crosslinked agarose beads. Several residues, for example histidine, form complexes with 
many metal ions. Charged with suitable ions (e.g.: Ni2+, Co2+,…) this column will selectively 
retain proteins with complex forming amino acids exposed on the surface. Chelating agents, 
as EDTA, should be avoided. Don’t use DTT as a reducing agent in protein samples, use β-
mercaptoethanol instead. His6-tagged proteins can be purified directly form pre-treated 
bacterial lysates.  
 
• Wash the sample pump with H2O to ensure that it is free of air. 
• Wash the column with 5 CV of H2O to wash away the 20% ethanol solution. 
• Load the column with 0.5 CV of 0.1 M NiCl2 or 0.1 M NiSO4. 
• Wash the column with 5 CV of H2O. 
• Choose a buffer system that is suitable for the analysis following the purification. 
• Degas the buffer solutions using a water jet pump and filtrate through a ZapCapS bottle 
top filter (0.2-0.45 μm). 
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• Flush the pumps, the valves and the sample applicator of the FPLC system with the 
buffer solutions. 
• Equilibrate the column with 5 CV of binding buffer (low imidazole buffer) until the base 
line is stable. 
• Optional: Wash the column with 5 CV elution buffer to elute unspecificaly bound metal 
ions and re-equilibrate with 5 CV of binding buffer. 
• Centrifuge the bacterial lysate at 4°C and 18000 rpm for at least 10 min to remove 
insoluble particles. 
• Load the supernatant onto the column using the sample pump. Be careful to load the 
sample at slow flow rates or alternatively more than once, to ensure binding of the His6-
tagged protein. 
• Wash with 5-10 CV of binding buffer. 
• Optional: Wash with 5 CV high salt buffer (binding buffer + 0.5-1 M NaCl) to eliminate 
ion exchange effects. Wash again with 5 CV of binding buffer. 
• Elute the protein with 2-5 CV (usually sufficient) of elution buffer (high imidazole 
buffer). 
  → also possible: linear gradient from 0-100% elution buffer  of e.g. 10-20 CV. 
• Collect fractions of the flow through and the eluate and analyse the samples by SDS-
PAGE. 
• After the purification, flush the FPLC system, strip the column with 5 CV stripping 
buffer, wash with 5-10 CV of H2O and eventually with 4 CV of 20% of ethanol for 
storage. From time to time wash the column with 2 CV of 0.5 M NaOH. 
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5.6.3. Anion exchange chromatography (Resource Q 6ml) 
 
Resource Q is a pre-packed column from pharmacia biotech. The matrix is composed 
of monodisperse polystyrene/divinyl benzene beads with quaternary ammonium as anion 
exchanger. It is suitable for purification of acidic proteins (pI < 7). The pH of the buffer 
should be at least 1 pH unit above the pI of the protein of interest so that it is negatively 
charged and will bind to the matrix. Anionic detergents should be avoided as they bind to 
quaternary ammonium. The practical protein loading range is up to 150 mg, whereas the 
sample volume is of minor importance. 
 
• Choose a buffer system that is not bound by the exchanger (e.g.: Tris×HCl) and prepare 
two buffer solutions, one with low ionic strength (e.g. 10 mM NaCl) and one with high 
ionic strength (e.g. 0.5 to 1 M NaCl). 
• Degas the buffer solutions using a water jet pump and filtrate through a ZapCapS bottle 
top filter (0.2 μm). 
• Flush the pumps, the valves and the sample applicator of the FPLC system with the 
buffer solutions. 
• Equilibrate the column with at least 2 CV of start buffer (low ionic strength buffer). 
• Run 2 CV of elution buffer (high ionic strength buffer) through the column. 
• Re-equilibrate the column with 5 CV of start buffer. 
• Centrifuge the bacterial lysate at 4°C and 18000 rpm for at least 10 min to remove 
insoluble particles. 
• Load the supernatant onto the column using the sample pump.  
• Wash with 5 CV of start buffer. 
• Elute the protein via gradient elution by mixing start and elution buffer over e.g. 20 CV. 
  → lower flow rates and more shallow gradients improve resolution. 
• Collect fractions of the flow through and the eluate and analyse the samples by SDS-
PAGE. 
• After the purification, flush the FPLC system, wash the column with 5-10 CV of H2O 
and eventually with ~ 5 CV of 20% ethanol for storage. From time to time clean the 
column with 5 CV 1 M NaCl, 5 CV 1 M NaOH, 5 CV 1 M HCl and 5 CV 1 M NaCl, 
before washing with H2O and storing in 20% ethanol. 
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5.6.4. Preparative size exclusion chromatography (HiLoad 16/60 
Superdex 75 prep grade) 
 
HiLoad 16/60 Superdex 75 prep grade is a pre-packed column from amersham 
pharmacia biotech. The matrix is produced by covalent bonding of dextran to highly cross-
linked agarose. The separation range of this column lies in the molecular weight range 
between 3 000 to 70 000, the bed volume is approximately 120 ml. Proteins applied to this 
column are separated according to their size. Large proteins elute first, while small proteins 
can enter the pores of the matrix and are thus retarded. This polishing step is mostly used as 
a last step in protein purification to achieve final high-level purity. 
 
• Choose a buffer system that is suitable for the analysis following the purification (e.g. 
sodium phosphate or Tris buffer at appropriate pH).  
• Degas the buffer solutions using a water jet pump and filtrate through a ZapCapS bottle 
top filter (0.2 μm). 
• Equilibrate the column with at least 2 CV of running buffer until the base line is stable. 
• Flush the pumps, the valves and the sample applicator of the FPLC system with the 
buffer solutions. 
• Dissolve the protein sample in 1 to 2% of the bed volume (up to 5 ml) of running buffer 
or concentrate to this volume. 
• Centrifuge the protein sample at 4°C and 18000 rpm for at least 10 min to remove 
insoluble particles. 
• Load the protein solution onto the column using a syringe (loop sample injection). 
• Elute the column with 1.5 CV of running buffer. 
• Collect fractions of the flow through and the eluate and analyse the samples by SDS-
PAGE. 
• If the resolution is low, decrease the flow rate or the sample volume or sample amount. 
To avoid nonspecific ionic interactions with the matrix, use buffers with ionic strength of 
at least 150 mM NaCl. Alternatively, gel filtration can be performed under denaturing 
conditions with buffers containing up to 8 M urea or up to 6 M guanidinium 
hydrochloride. 
• After the purification, flush the FPLC system and wash the column with a minimum of 3 
CV of water and eventually with 4 CV of 20% of ethanol (wash the column from time to 
time with 0.5 CV of 0.5 M NaOH). 
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5.6.5. Analytical size exclusion chromatography (Superdex 75 
10/300 GL) 
 
Superdex 75 10/300 GL is a pre-packed column from GE Healthcare. The matrix 
consists of a composite of cross-linked agarose and dextran. The separation range of this 
column lies in the molecular weight range between 3 000 to 70 000, the bed volume is 
approximately 24 ml. The column efficiency, expressed as the number of theoretical plates per 
meter is > 30 000 N/m. Proteins applied to this column are separated according to their size. 
This column is for analytical purposes, the amount of protein loaded onto the column should 
be ≤ 10 mg in a volume of 25-500 µl. 
 
• Choose a buffer system that is suitable for the analysis.  
• Degas the buffer solutions using a water jet pump and filtrate through a ZapCapS bottle 
top filter (0.2 μm). 
• Wash the column with at least 2 CV of H2O. 
• Equilibrate the column with at least 2 CV of running buffer until the base line is stable. 
• Flush the pumps, the valves and the sample applicator of the FPLC system with the 
buffer solutions. 
• Centrifuge the protein sample at 4°C and 18000 rpm for at least 10 min to remove 
insoluble particles. 
• Load 25-500µl protein solution onto the column using a syringe (loop sample injection). 
  → not more than 10 mg protein. 
• Elute the column with 1.5 CV of running buffer. 
• Collect fractions of the flow through and the eluate and analyse the samples by SDS-
PAGE. 
• After the purification, flush the FPLC system and wash the column with a minimum of 3 
CV of water and eventually with 4 CV of 20% of ethanol (wash the column from time to 
time with 1 CV of 0.5 M NaOH). 
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5.7. Quantification of protein 
 
 
Bradford assay (Coomassie Blue protein assay) 
 
The absorbance maximum of the dye in an acidic solution shifts from 465 to 595 nm 
after adding protein due to stabilization of the anionic form of the dye by both hydrophobic 
and ionic interactions. The dye principally reacts with arginine residues and to a lesser extent 
with histidine, lysine, tyrosine, and phenylalanine residues. 
 
Preparation of a calibration curve: 
 
• Prepare a 0.1 µg/µl BSA solution in H2O. 
• Prepare 11 aliquots with 0 µg, 1 µg, 2 µg, 3 µg, 4 µg, 5 µg, 6 µg, 7 µg, 8 µg, 9 µg and 
10 µg of BSA in 100 µl H2O and transfer to polystyrene cuvettes for measurement in a 
photometer. 
• Mix each aliquot with 1ml of Bradford reagent and let stand for ~ 2 min. 
• Measure the absorbance at 595 nm.  
• Establish the calibration curve. 
 
Measurement of protein samples: 
 
• 5 µl of protein sample are diluted with H2O to a final volume of 100 µl. 
• Add 1ml of Bradford reagent and let stand for ~ 2 min. 
• Measure the absorbance at 595 nm.  
• Calculate protein concentration with the help of the calibration curve. 
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5.8. TEV protease cleavage of proteins 
 
TEV protease is the name for the 27 kDa catalytic domain of the Nuclear Inclusion a 
(NIa) protein of the tobacco etch virus (TEV). TEV protease recognizes highly specific a 
linear epitope of the general form EXXYXQ’(G/S), with the cleavage occurring between Q 
and G or S. The most efficient and most commonly used substrate is ENLYFQS. TEV protease 
is maximally active at 34°C, but it is recommended to perform digests at room temperature or 
at 4°C overnight. The “standard” reaction buffer for TEV protease is 50 mM Tris×HCl (pH 
8.0), 0.5 mM EDTA and 1 mM DTT, but it tolerates a range of buffers, including phosphate, 
MES and acetate. The cleavage can be inefficient, if the cleavage site is too close to ordered 
structures or the substrate exits in the form of soluble aggregates [176]. 
 
Initial screen for TEV protease – substrate ratio determination: 
 
• Measure protein concentrations of TEV protease and protein sample. 
• Mix TEV protease and the protein sample in the ratios 1:50, 1:100, 1:250 and 1:500 in a 
fixed volume of TE buffer (e.g.: 20 µl) and a fixed amount of protein (e.g.: 20 µg per 
digest). 
• Mix the digestion mixture carefully. 
• Cleave at 4°C o/n. 
• Analyze the samples by SDS-PAGE. 
• Depending on the outcome of the cleavage, enhance or reduce the amount of TEV 
protease. 
• If the perfect conditions are found, scale up the experiment. 
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5.9. SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
of proteins [177] 
 
 
SDS-PAGE is used for the investigation of protein samples in terms of contained 
proteins. Gels containing sodium dodecyl sulfate (SDS) provide dissociating conditions, 
where proteins are separated strictly according to polypeptide size. A discontinuous buffer 
system [178, 179] and polyacrylamide (PAA) concentrations from 10%-20% were used. As 
molecular weight markers served Unstained Protein Molecular Weight Marker SM0431 
(Fermentas) (14.4, 18.4, 25, 35, 45, 66.2, 116 kDa), SDS7 (Sigma Aldrich) (14.2, 20.1, 24, 29, 
36, 45, 66 kDa), SDS6H2 (Sigma Aldrich) (29, 45, 66, 97, 116, 200 kDa) and the Ultra-low 
Range Molecular Weight Marker M3546 (Sima Aldrich) (1.060, 3.496, 6.5, 14.2, 17.0, 26.6 
kDa). 
 
 
15% gels were used most often and cast using the Mini-PROTEAN 3 Multi-
Casting Chamber (BIORAD). 
 
 12 resolving gels 12 stacking gels 
Tris (pH 9.0) 8 ml - 
Tris (pH 6.8) - 3.5 ml 
40% PAA (37.5 : 1) 24 ml - 
40% PAA (19 : 1) - 3.5 ml 
H2O 32 ml 21 ml 
       degas  
20% SDS 320 μl 70 μl 
TEMED 20 μl 35 μl 
APS 200 μl 140 μl 
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Protocol for gels with specific percentage: 
• Clean glass plates, spacers and combs with iso-propanol to remove contaminants 
(proteins and lipids) and let them dry. 
• Assemble the glass plates separated by spacers leakproof according to the 
manufacturer’s instructions. 
• Mark the height of the separating gel (~ 1 cm beneath the comb teeth) 
 
Separation gel: 
 [10 % – 20 % acrylamide, 0.27 % – 0.55 % bisacrylamide, 390 mM Tris×HCl (pH 9.0), 0.1 % SDS] 
 
o Mix acrylamide solution (33%) with H2O according to the table (in a 100ml 
suction flask, if you want to degas → not necessary) and add solutions given 
below. 
 
separation gel 
acrylamide/bisacrylamide 
(separation gel) 
H2O 
10% 
11% 
12% 
13% 
14% 
15% 
16% 
17% 
18% 
19% 
20% 
5.3 ml 
5.8 ml 
6.4 ml 
6.9 ml 
7.4 ml 
8.0 ml 
8.5 ml 
9.0 ml 
9.6 ml 
10.1 ml 
10.6 ml 
9.9 ml 
9.4 ml 
8.9 ml 
8.3 ml 
7.8 ml 
7.3 ml 
6.7 ml 
6.2 ml 
5.7 ml 
5.2 ml 
4.6 ml 
 
Tris×HCl 3 M (pH 9.0) 2.28 ml 
20% SDS 90µl 
TEMED 10µl 
APS 67µl 
 
o Mix thoroughly and pipete the solution between the glass plates up to the marked 
line, overlay with ~ 1 ml H2O saturated butanol and let the gel polymerize (~ 20 
min, check excess solution). 
 67 
Stacking gel:  
 [4.5 % acrylamide, 0.22 % bisacrylamide, 125 mM Tris×HCl (pH 6.8), 0.15 % SDS] 
 
o before adding TEMED and APS decant the butanol from the polymerized 
separation gel, wash with deionized H2O and get rid of excess H2O using a 
paper towel 
 
 
acrylamide/bisacrylamide 
(stacking gel) 
2.25 ml 
H2O 6.25 ml 
Tris×HCl 1 M (pH 6.8) 1.25 ml 
20% SDS 75µl 
TEMED 20µl 
APS 100µl 
 
• Mix thoroughly and pipete the solution onto the separation gel. 
• Immediately insert a comb (avoid trapping air bubbles) and let the gel polymerize         
(~ 1 h, check excess solution). 
• Mount the gel into a vertical electrophoresis chamber filled with Laemmli buffer, 
remove the comb and flush the wells. 
• Load the samples (in 1x protein sample buffer) onto the gel (0.5-5 µg protein/sample). 
 → optional: samples (in 1x protein sample buffer) might be heated to 95°C for 
~ 3 min to fully denature proteins; centrifuge briefly before loading. 
• Run the gel at 200 V for ~ 40 min (until the bromphenol blue reaches the bottom of the 
separating gel). 
→ optional: nicest results (less ‘smiley’ effect, sharper bands) are observed, 
applying 8 V/cm voltage for the stacking gel and 15 V/cm voltage for the 
separating gel. Be aware that the running time is highly prolonged. 
• Incubate the gel in Coomassie staining solution for at least 30 min. 
→ for observing very small peptides (< 5 kDa) the gel has to be washed for 5-
10 min in H2O, fixed in freshly prepared 5 % glutaraldehyde for 1 h (to prevent 
small peptides from diffusing out) and washed 3 times for 5 min in H2O before 
incubation in Coomassie staining solution. 
• Destain the gel in destaining solution until the gel is colourless again, except the protein 
bands. 
• Take a picture of the gel with a Gel Doc System (Sony). 
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5.10. Pull-Down Assay 
 
One way to determine physical interaction between two or more proteins is the pull-
down technique, which resembles immunoprecipitation, except that a tagged bait protein is 
used instead of an antibody. Usually His6 and GST (glutathione S-transferase) are used as 
fusion tags. The tagged bait protein is then bound by an immobilized affinity ligand specific 
for the tag, glutathione agarose for GST-tagged proteins or immobilized bivalent metal ion 
matrices for His6-tagged proteins. A solution containing potential interaction partners (prey 
proteins) is subsequently applied on the immobilized bait protein. 
 
Two different approaches: 
a) The hypothetical prey protein is expressed and purified in an artificial protein expression 
system and tested for binding to the immobilized His6-tagged bait protein. Usually, the 
large amount of purified protein allows confirmation of the pull-down by SDS-PAGE 
and conventional Coomassie staining. This type of pull-down strategy is usually used to 
confirm a suspected interaction.  
b) Cellular lysate containing the suspected endogenous prey protein is used during the pull-
down assay. In this case, pull-down is confirmed by SDS-PAGE and subsequent western 
blot using antibodies directed against the prey protein.  
 
ad a) 
The pull-down assay was performed on HiTrap Chelating HP 5ml: 
• Prepare the column as described above (→ section 5.6.2: “Immobilized metal ion 
affinity chromatography (HiTrap Chelating HP 5ml)”) 
• After equilibration of the column centrifuge the His6-tagged bait protein sample at 4°C 
and 18000 rpm for at least 10 min to remove insoluble particles. 
• Load the supernatant onto the column using the sample pump.  
 → load the sample at slow flow rates or alternatively more than once, to 
ensure binding of the His6-tagged protein. 
• Wash with 5-10 CV of binding buffer. 
• Centrifuge the purified prey protein sample at 4°C and 18000 rpm for at least 10 min to 
remove insoluble particles. 
• Load the supernatant onto the column using the sample pump 
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→ load the prey protein sample at slow flow rates or alternatively let incubate 
for a certain time (1 h) to allow interaction. 
• Elute the proteins with 2-5 CV of elution buffer (high imidazole buffer). 
• Collect fractions of the flow through and the eluate and analyse the samples on an SDS-
PAGE. 
• After the pull-down assay, flush the FPLC system, strip the column with 5 CV stripping 
buffer, wash with 5-10 CV of H2O and eventually with 4 CV of 20% of ethanol for 
storage. From time to time wash the column with 2 CV of 0.5 M NaOH. 
 
ad b) 
The pull-down assay was performed on HiTrap Chelating HP 1ml: 
  → Co2+ was used, instead of Ni2+, as it seems to be less prone to unspecific binding of 
proteins 
  → usually, a small peristaltic pump was used for this experiment 
• Prepare the column as described above (→ section 5.6.2: “Immobilized metal ion 
affinity chromatography (HiTrap Chelating HP 5ml)”) 
• Optional: Pre-clearing of the cell lysate: 
As there are proteins in a cellular lysate, which are able to interact with bivalent ions by 
themselves, it might be of interest to pre-clear the lysate. Alternatively, buffers with high 
ionic strength can be used to inhibit unspecific binding. A drawback of high ionic 
strength is that it might interfere with the specific interaction between the bait and the 
prey protein. 
o Centrifuge the cell lysate at 4°C and 18000 rpm for at least 10 min to remove 
insoluble particles. 
o Load the supernatant of the cell lysate onto the column. 
o Elute with ~ 5 CV of binding buffer and collect the flow through 
→ this flow through fraction is the pre-cleared cell lysate and should be devoid 
of proteins that bind unspecificaly to the Co2+ column. 
o Elute with ~ 5 CV of elution buffer  
 → contains proteins that bind unspecificaly to the Co2+ column. 
o Re-equilibrate the column with 5-10 CV binding buffer 
 → optional: recharge the column with Co2+ 
• After equilibration of the column centrifuge the His6-tagged bait protein sample at 4°C 
and 18000 rpm for 10 min or more. 
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• Load the supernatant onto the column. 
 → load the sample at slow flow rates (or alternatively more than once, to 
ensure binding of the His6-tagged protein). 
• Wash with 5-10 CV of binding buffer. 
• Centrifuge the cell lysate at 4°C and 18000 rpm for 10 min or more. 
• Load the supernatant of the cell lysate onto the column or – with additional pre-clearing 
– load the pre-cleared cell lysate onto the column. 
→ load the cell lysate at very slow flow rates or alternatively let incubate for a 
certain time (1 h) to allow interaction. 
• Elute the proteins with 2-5 CV of elution buffer (high imidazole buffer). 
• Collect fractions of the flow through and the eluate and analyse the samples via SDS-
PAGE and subsequent western blot with antibodies directed against the prey protein. 
• After the pull-down assay strip the column with 5 CV stripping buffer, wash with 5-10 
CV of H2O and eventually with 4 CV of 20% of ethanol for storage. From time to time 
wash the column with 2 CV of 0.5 M NaOH. 
 
 
 
5.11. Western blot 
 
The western blot (alternatively, immunoblot) is a method of detecting specific proteins 
within a mixture of proteins with the help of specific antibodies. Depending on the method of 
detection very little amounts of protein can be detected.  
Samples, to be tested for containing the protein in question, are separated by SDS-
PAGE and subsequently blotted onto a nitrocellulose membrane by applying an electric 
current orthogonal to the gel and membrane. The negatively charged proteins (SDS) migrate 
out of the gel and are bound by the nitrocellulose membrane via hydrophobic as well as 
charged interactions, maintaining the migration pattern of the polyacrylamide gel. 
Subsequently, a specific protein can be detected with primary antibodies directed against that 
protein. Methods of detection are colorimetric, chemiluminescent, radioactive and fluorescent 
detection and often involve enzymes fused to the secondary antibody directed against the Fc 
domain of the primary antibody. The reaction catalyzed by the bound enzyme is used to detect 
specific bands corresponding to the protein in question. 
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Transfer (Tank Blot system): 
 
• Run a gel suitable for Western blotting. 
  → optional: run at the same time a second gel for Coomassie staining. 
• Submerge a nitrocellulose membrane of suitable size shortly in H2O.  
• Equilibrate the nitrocellulose membrane in transfer buffer. 
 → work with gloves as the transfer buffer contains methanol; touch the membrane 
only with forceps (be aware that the nitrocellulose strongly binds proteins). 
• Soak 2 sponges and 4 sheets of Whatman paper (same size as sponges) in transfer buffer. 
• Cut upper right edge of gel and nitrocellulose membrane to remember orientation. 
• Set up the transfer sandwich (from anode to cathode): 
→ !! no bubbles !! 
o Sponge 
o 2x Whatman paper 
o Nitrocellulose membrane 
o Gel 
o 2x Whatman paper 
o Sponge 
• Blot at a constant current of 60 mA at 4°C o/n. 
• On the next day increase current to 250 mA and blot for additional 2 h. 
  → for high percentage gels (> 15 %) blot ~ 3.5 h. 
• Optional: stain the gel from the transfer with Coomassie staining solution to check 
effectiveness of the blotting. 
• Wash the nitrocellulose membrane with H2O. 
• Stain for 2 min in Ponceau-S staining solution, rinse with H2O and mark the protein 
marker bands with a ball pen. 
• Destain with 1x PBS for 30 min. 
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Detection with the AP-system (alkaline phosphatase): 
 
• Blocking → put the membrane in 100 ml blocking solution at 4°C o/n (or 1 h at room 
temperature). 
• 1st antibody → apply first antibody (1:200 to 1:1000 diluted in 5 ml blocking solution) in 
a conical tube on a stirrer for 1 h at room temperature or 4°C o/n. 
• Washing → wash 3 x 10 min with PBS-T. 
• 2st antibody → apply second antibody (alkaline phosphatase coupled; 1:1000 anti-mouse 
or 1:5000 anti-rabbit diluted in 1 part blocking solution and 2 parts PBS-T) in a conical 
tube on a stirrer for 1.5 h at room temperature. 
• Washing → wash 3 x 10 min with PBS-T and rinse briefly with H2O. 
• Detection → detect with 10 µl NBT solution, 5 µl BCIP solution in 10 ml AP-buffer for ~ 
10 min. 
• Wash → wash with H2O to stop the reaction and store light-protected. 
 
 
 
 
5.12. Circular dichroism spectroscopy of proteins 
 
Circular dichroism (CD) is defined as the difference in absorption of left and right 
handed circular-polarized light ΔA = AL – AR by chromophores in an asymmetrical 
environment, resulting in elliptically polarized light. CD spectroscopy can be used to get 
information about the structure of macromolecules (including the secondary structure of 
proteins and the handedness of DNA). The most commonly used unit in CD spectroscopy of 
proteins is the mean residue ellipticity [degree cm² dmol-1], which is obtained by 
normalization with sample concentration, path length of the cell and with the number of 
residues. The mean residue ellipticity is measured as a function of wavelength.  
For gaining information about the secondary structure of proteins, CD spectra need to 
be recorded from about 260 nm to ~ 185 nm (far UV). At these wavelengths the amide groups 
of the peptide backbone interact with the entering circularly-polarized light. Spectra can be 
analyzed for different secondary structural types: alpha helix, parallel and antiparallel beta 
sheet, random coil, etc.  
Fig. 8 shows typical CD spectra of different secondary structural elements.  
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Experimental conditions: 
• Buffer: 
Buffers must be as transparent as possible and should exhibit low absorbance in the region 
of interest (260-180 nm). Sodium or potassium phosphate buffers are suitable for CD 
measurement. Try to avoid organic buffers and detergents (e.g.: imidazole, DTT, 
histidine), as they absorb below 220 nm. Chloride ions (e.g.: HCl, NaCl) interfere with 
CD measurement and should be avoided. 
• Sample concentration: 
Accurate CD measurements are not possible at an absorbance above 1.0. For calculation 
of the starting molar concentration the following equation is useful: 
 c = 115 / (molecular weight × cell length [cm] × 7000) 
• Path length: 
The smaller the path length of the cell, the lower is the absorption by the solvent. Small 
path lengths will permit scanning down to lower wavelengths. 
• Filtration: 
Filtering the samples and the buffer through a 0.2-0.45 µm filter will remove dust, 
aggregated protein and other particles that interfere with CD measurements. 
• CD Spectrometer: 
CD spectra were recorded on a spectropolarimeter (Applied Photophysics π*-180). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Typical CD spectra of 
different secondary structural 
elements (far UV). Spectrum α-helix 
(red); β-sheet (blue); random coil 
(black). The ordinate shows the 
difference in absorption of left and 
right handed circular-polarized light 
ΔA = AL – AR as a function of the 
wavelength in nm. 
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6. Cell Culture 
 
6.1. Preparation of cellular extract 
 
• Discard the medium from the cells in the cell culture plates (→ 100 mm culture dishes). 
  → suck off with a water jet pump. 
• Wash the cells with 3-5 ml of PBS and discard PBS completely. 
• Cover the cells with 1 ml NDL buffer per plate. 
• Pivot the plates on ice for 15-20 min. 
• Scrape the cells from the plate floor and pipette the lysate into 2 ml Eppendorf tubes. 
• Centrifuge at 4°C and 15000 rpm for 60 min. 
• Transfer the supernatant (containing cellular proteins) into a new tube. 
• Quantify the protein content (use 2.5 µl cellular extract for the Bradford assay). 
• Store the cellular extract at -80°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
7. Specific protocols 
 
7.1. Expression and purification of His6-Carrier-cBASP1 
peptide fusion proteins 
 
7.1.1. Construction of expression vectors coding for His6-Carrier-
cBASP1 peptide fusion proteins 
 
pETGB_1a, pETMBP_1a, pETNus_1a, pETtrx_1a and pETZ2_1a were kindly 
provided by Günter Stier. They code for His6-Carrier-GFP fusion proteins including a TEV 
cleavage site between the Carrier and GFP. During the cloning procedure, the DNA stretch 
coding for GFP is cleaved out and substituted by the DNA sequence of interest. The features 
of this expression system are listed below.  
 
 
Features: 
His6 N-terminal His6 tag; binds bivalent ions (Ni
2+, Co2+,…); for purification on 
metal chelating columns 
TEV cleavage site Between the carrier and the target protein; allows cleavage of the target protein from the carrier with a TEV protease. 
T7 promoter For expression systems using T7 RNA polymerase 
KanR Kanamycin resistance 
GFP Green fluorescent protein; default protein 
Carriers (solubility enhancement tags): 
GB1 
B1 Ig binding domain of Streptococcus; can stabilize aggregation prone 
proteins; binds independently to secondary antibodies, which can be used for 
detection of passenger protein in the fusion state; in NMR studies used as 
myristolyated product via coexpression of a modifying  coenzyme to anchor in 
lipid bilayers 
[His6-GB1-TEV after Tev cleavage Mw = 8575.6 Da] 
MBP 
Maltose-binding protein; chaperone function; binds independently to amylose 
columns 
[His6-MBP-TEV after Tev cleavage Mw = 42947.65 Da] 
NusA Highly soluble protein [His6-NusA-TEV after Tev cleavage Mw = 57264.51 Da] 
trx Thioredoxin protein; highly stable and soluble [His6-trx-TEV after Tev cleavage Mw = 14213.21 Da] 
Z2 
Gene fragment of staphylococcal protein A; IgG binding; highly stable and 
soluble 
[His6-Z2-TEV after Tev cleavage Mw = 10172.15Da] 
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To construct the expression vectors coding for the His6-Carrier-cBASP1 peptide 
fusion proteins, pA-cBASP1 (kindly provided by T. Matt), containing cBASP1 cDNA, was 
used as a template to subclone the cBASP1 peptide (cBASP1 residues 60 – 80: 
KVEKDAQVSANKTEEKEGEKE) C-terminally to the respective carrier protein. To stay in 
frame with the carrier protein, two additional bases had to be introduced, resulting in an 
additional glutamic acid residue, which corresponds to residue 59 of cBASP1. PCR was 
performed using primers, which recognize the DNA stretch coding for the target cBASP1 
peptide and added at the 5’ end an NcoI and at the 3’ end a stop-codon and a NotI restriction 
site [gradient PCR: 5’ at 95°C; 30 cycles of (20’’ at 95°C; 20’’ at 53°C / 56°C / 60°C; 20’’ at 
72°C); 5’ at 72°C; hold at 4°C]. The PCR-product was directly NcoI/NotI digested and 
purified by phenol:cholorform extraction and subsequent iso-propanol precipitation. The 
expression vectors were digested with the same enzymes, treated with CIP, to remove 5’ 
phosphate groups, and purified (QIAgen PCR purification kit). Finally, the digested PCR-
product was ligated with the digested and CIP treated expression vector. All constructs (pET-
His6-GB1-cBASP1pep, pET-His6-MBP-cBASP1pep, pET-His6-NusA-cBASP1pep, pET-
His6-trx-cBASP1pep and pET-His6-Z2-cBASP1pep) were verified by sequencing (VBC 
biotech sequencing service → www.vbc-biotech.at). As a matter of simplicity, in the 
following text the term ‘Ca’ will substitute for each individual Carrier protein (GB1, MBP, 
NusA, trx, Z2). 
 
Primers: 
 
fw(Nco1)BASPfrag: 5’ TAAATACCATGGAGAAGGTTGAGAAGGATGCTCAGGTC 
 
rev(Not1)BASPfrag: 5’ ATTAATGCGGCCGCTCACTCTTTCTCCCCTTCTTTTTCTTC 
 
XXX   →  buffer bases, to ensure high restriction efficiency 
XXX  →  restriction enzyme recognition site 
XXX  →  stop codon 
XXX  →  additional bases to stay in frame with the carrier protein 
 
 
 
 
 
 
 
 
 77 
7.1.2. Expression and purification of His6-Carrier-cBASP1 peptide 
fusion proteins 
 
pET-His6-‘Ca’-cBASP1pep was transformed into the E. coli strain 
Rosetta(DE3)pLysS. A 20 ml overnight culture prepared in LB-medium supplemented with 
chloramphenicol (25 µg/ml) and kanamycin (25 µg/ml) was diluted 1:100 in 1 l LB-medium 
(+ CoA + Kan) or in M9 minimal medium (+ CoA + Kan). M9 minimal medium substituted 
with 13C-glucose and/or 15NH4Cl is used for 13C and 15N labelling necessary for NMR 
analysis. In this study, unlabeled M9 minimal medium was used just to test, if transformed 
bacteria grow and express recombinant proteins also under minimal conditions. Bacteria were 
grown at 37°C and 225 rpm in 2 l baffled Erlenmeyer flasks until an OD600 of 0.5 to 1.0. 
Recombinant protein synthesis was induced by the addition of 1 ml 0.4 M IPTG (final 
concentration 0.4 mM IPTG) and incubation was continued for 3 h. Subsequent steps were 
carried out at 4°C. Bacteria were collected by centrifugation and the pellet was resuspended in 
30 ml lysis buffer (20mM Tris×HCl pH 7.4, 1mM EDTA, 1mM β-mercaptoethanol). The 
bacterial suspension was frozen in liquid nitrogen and stored at -20°C. For purification, the 
frozen suspension was thawed carefully, sonicated (to lyse the cells and fragment the DNA) 
and centrifuged. The clear solution containing soluble proteins was loaded onto a Ni2+ column 
(HiTrap Chelating HP 5ml amersham pharmacia) equilibrated in low imidazole buffer, 
washed with low imidazole buffer and eluted with high imidazole buffer. Depending on the 
carrier protein, the recombinant protein was eluted more or less clean from the Ni2+ column 
deduced from Coomassie stained SDS-polyacrylamide gels. For example, His6-NusA-
cBASP1pep was still quite contaminated compared to His6-GB1-cBASP1pep, which was 
already eluted very clean. Therefore, an additional preparative gel filtration step (HiLoad 
16/60 Superdex 75 prep grade) was performed, depending on the outcome of the Ni2+ affinity 
chromatography.  
 
a) The protein sample was pure after Ni2+ affinity chromatography. 
The protein sample was transferred to a Centriprep filter (Amicon) with a cut off value 
smaller than the molecular weight of the protein. The high imidazole buffer was 
exchanged by buffer suitable for following experiments (Tris×HCl 20 mM pH 7.4) by 3 
to 4 times of concentrating the protein sample and subsequent dilution in the target 
buffer. Finally the protein sample was concentrated to 0.5-1.5 ml (Centriprep), 
substituted with EDTA (1 mM) and β-mercaptoethanol (1 mM) and stored at -20°C. 
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b) The protein sample is not pure enough, additional gel filtration is required. 
The protein sample was concentrated to 0.5-1 ml by centrifugation through a Centriprep 
filter with a cut off value smaller than the molecular weight of the protein, centrifuged 
and loaded onto a HiLoad 16/60 Superdex 75 prep grade gel filtration column 
equilibrated in target buffer (Tris×HCl 20 mM pH 7.4). Protein containing fractions 
were analyzed by SDS-PAGE. Pure fractions were pooled, concentrated to 0.5-1.5 ml 
(Centriprep), substituted with EDTA (1 mM) and β-mercaptoethanol (1 mM) and stored 
at -20°C.  
 
 
 
7.2. Expression and purification of the MC29EB protein 
 
7.2.1. The expression vector coding for MC29EB protein 
 
pET3d-MC29EB was constructed by T. Matt (diploma thesis, 1997) and encodes a 
part of the v-Myc oncogene from the MC29 virus corresponding to residues 440-453 of the 
viral Gag protein – plus an N-terminal methionine – fused to six amino acids encoded by the 
5’ untranslated region of the chicken c-myc gene plus a stretch of 140 residues corresponding 
to the N-terminus of chicken c-Myc (residues 1-140). Residue 140 (Thr) of chicken c-Myc 
corresponds to residue 151 (Ser) of human c-Myc.  
Recombinant MC29EB has a molecular weight of 17.8 kDa, but migrates at an 
apparent molecular weight of ~ 21 kDa. 
 
 
7.2.2. Expression and purification of the MC29EB protein 
 
MC29EB was purified in principle according to the protocol described (T. Matt, 
diploma thesis, 1997). pET3d-MC29EB was transformed into the E. coli strain 
Rosetta(DE3)pLysS. A 20 ml overnight culture prepared in LB-medium supplemented with 
chloramphenicol (25 µg/ml) and ampicillin (100 µg/ml) was diluted 1:100 in 1 l LB-medium 
(+ CoA + Amp) or in M9 minimal medium (+ CoA + Amp). Bacteria were grown at 37°C and 
225 rpm in 2 l baffled Erlenmeyer flasks until an OD600 of 0.5 to 1.0. Recombinant protein 
synthesis was induced by the addition of 1 ml 0.4 M IPTG (final concentration 0.4 mM IPTG) 
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and incubation was continued for 3 h. Subsequent steps were carried out at 4°C. Bacteria were 
collected by centrifugation and the pellet was resuspended in 30 ml lysis buffer (20mM 
Tris×HCl pH 7.4, 1mM EDTA, 1mM β-mercaptoethanol). The bacterial suspension was 
frozen in liquid nitrogen and stored at -20°C. For purification, the frozen suspension was 
thawed carefully, sonicated (to lyse the cells and fragment the DNA) and centrifuged. 
MC29EB is insoluble expressed in inclusion bodies; hence, after centrifugation, MC29EB is 
in the pellet. The supernatant was discarded, the inclusion bodies enriched (→ section 5.3: 
“Enrichment of inclusion bodies”) and dissolved in 5 ml TEU buffer. 
 
a) The sample still suffering from impurities is later used for pull-down assays. 
MC29EB dissolved in TEU buffer was stepwise dialyzed into the target buffer (20 mM 
Tris×HCl pH 7.4) (→ section 5.4: “Refolding of proteins using stepwise dialysis”), 
concentrated to 0.5-1.5 ml (Centriprep), substituted with EDTA (1 mM) and β-
mercaptoethanol (1 mM) and stored at -20°C. 
 
b) The protein sample needs to be further purified for e.g. CD measurement. 
MC29EB was purified via anion exchange chromatography under denaturing conditions. 
Therefore the protein sample (in TEU buffer) was loaded onto an anion exchange 
column (Resource Q 6 ml) equilibrated in TEU buffer, washed with TEU buffer and 
eluted via gradient elution from 0-30% TEUS buffer over 20 CV. MC29EB was eluted 
from ~ 40 mM NaCl to ~ 200mM NaCl, but was predominantly eluted in 2 peaks. As a 
matter of fact, the sharp elution in 2 peaks at 53 mM NaCl and 179 mM NaCl as 
described before (T. Matt, diploma thesis, 1997) could not be reproduced. In fact, the 
elution of those 2 major peaks seemed to be dependent on the steepness of the gradient 
(see table below). Usually MC29EB was eluted purer in peak 2. 
 
 
 
 
 
 
 
 
 
 Peak 1 at Peak 2 at  
0-50% TEUS over 20 CV 75 mM NaCl 175 mM NaCl  
0-30% TEUS over 20 CV 50 mM NaCl 149 mM NaCl 
Best resolution and best purity of 
MC29EB in peak 2 
0-30% TEUS over 5 CV 152 mM NaCl 230 mM NaCl 
Worst resolution and comparably 
small peak 2 
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Alternatively, a stepwise gradient was tried for elution, which didn’t seem to produce 
better results: 
 
 
 
 
 
 
 
 
 
Purest fractions were pooled, optionally concentrated to a volume suitable for dialysis 
(Centriprep filter), stepwise dialyzed into the target buffer (20 mM Tris×HCl pH 7.4) 
(→ section: “Refolding of proteins using stepwise dialysis”) and concentrated to 0.5-1.0 
ml (Centriprep filter). Subsequently, the protein sample was centrifuged and loaded onto 
a HiLoad 16/60 Superdex 75 prep grade gel filtration column equilibrated in target 
buffer (20 mM Tris×HCl pH 7.4). Protein containing fractions were analyzed by SDS-
PAGE. Nearly pure MC29EB was observed at a retention volume of 56-58 ml (Kav = 
0.200-0.225). Pure fractions were pooled, concentrated to 0.5-1.5 ml (Centriprep), 
substituted with EDTA (1 mM) and β-mercaptoethanol (1 mM) and stored at -20°C.  
 
 
 
7.3. Expression and purification of His6-Minimax 
 
7.3.1. Construction of the expression vector coding for His6-
Minimax 
 
pET3d-p14max was constructed by Martin Schneider (doctoral thesis, 2002). This 
expression vector encodes a 92 amino acids peptide termed Minimax (p14max) encompassing 
amino acid residues 22-113 of chicken Max with an additional N-terminal methionine residue. 
pET-His6-Minimax was constructed using pET3d-p14max as a template to subclone the 
Minimax peptide C-terminally to the His6 tag encoded by the expression vector pET-M11. 
pET-M11 was kindly provided by Günter Stier. It codes for a His6-MAD fusion protein 
Linear gradient 0-4% TEUS 2 CV 
Constant elution 4% TEUS 2 CV 
Linear gradient 4-10% TEUS 2 CV 
Constant elution 10% TEUS 2 CV 
Linear gradient 10-15% TEUS 2 CV 
Constant elution 15% TEUS 2 CV 
Linear gradient 15-20% TEUS 2 CV 
Constant elution 20% TEUS 2 CV 
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including a TEV cleavage site between the His6 tag and MAD. During the cloning procedure, 
the DNA stretch coding for MAD is cleaved out and substituted by the DNA sequence of 
interest. pET3d-p14max was BamHI/NcoI digested, separated on a preparative agarose gel 
and the DNA band corresponding to the Minimax sequence was gel extracted (QIAgen gel 
extraction). pET-M11 was digested with the same enzymes, treated with CIP, to remove 5’ 
phosphate groups, and purified (QIAgen PCR purification kit). Finally, the digested and gel 
extracted Minimax sequence was ligated with the digested and CIP treated pET-M11 vector. 
The resulting pET-His6-Minimax expression plasmid was verified by sequencing (VBC 
biotech sequencing service → www.vbc-biotech.at). The His6-Minimax protein encoded by 
pET-His6-Minimax is cleavable by TEV protease to allow cleavage of the Minimax protein 
from the His6 tag. 
 
 
7.3.2. Expression and purification of His6-Minimax 
 
pET-His6-Minimax was transformed into the E. coli strain BL21(DE3)pLysS. A 20 ml 
overnight culture prepared in LB-medium supplemented with chloramphenicol (25 µg/ml) 
and kanamycin (25 µg/ml) was diluted 1:100 in 1 l LB-medium (+ CoA + Kan). Bacteria 
were grown at 37°C and 225 rpm in 2 l baffled Erlenmeyer flasks until an OD600 of 0.5 to 1.0. 
Recombinant protein synthesis was induced by the addition of 1 ml 0.4 M IPTG (final 
concentration 0.4 mM IPTG) and incubation was continued for 3 h. Subsequent steps were 
carried out at 4°C. Bacteria were collected by centrifugation and the pellet was resuspended in 
30 ml lysis buffer (20mM Tris×HCl pH 7.4, 10mM imidazole, 1mM EDTA, 1mM β-
mercaptoethanol). The bacterial suspension was frozen in liquid nitrogen and stored at -20°C. 
For purification, the frozen suspension was thawed carefully, sonicated (to lyse the cells and 
fragment the DNA) and centrifuged. The clear solution containing soluble proteins was 
loaded onto a Ni2+ column (HiTrap Chelating HP 5ml amersham pharmacia) equilibrated in 
low imidazole buffer, washed with low imidazole buffer and eluted with high imidazole 
buffer. The protein sample was transferred to a Centriprep filter (Amicon) with a cut off value 
smaller than the molecular weight of the protein. The high imidazole buffer was exchanged by 
buffer suitable for following experiments (20 mM Tris×HCl pH 7.4) by 3-4 times of 
concentrating the protein sample and subsequent dilution in the target buffer. Finally the 
protein sample was concentrated to 0.5-1.5 ml (Centriprep), substituted with EDTA (1 mM) 
and β-mercaptoethanol (1 mM) and stored at -20°C. 
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Results 
 
Investigation of direct interaction between c-Myc 
and the cBASP1 interacting peptide 
 
We hypothesized that chicken BASP1 (cBASP1) directly interacts with the 
transactivation domain (TAD) of c-Myc via a small stretch of amino acids comprising 
cBASP1 residues 60-80, based on the following observations:  
 Transformation of chicken embryonic fibroblasts (CEF) by the MC29 virus (encoding 
oncogenic v-Myc) is followed by the downregulation of cBASP1 already at the 
transcriptional level (unpublished data). 
 Ectopic expression of cBASP1 in CEF is counteracting transformation by the MC29 virus 
and leads to the downregulation of endogenous c-Myc (unpublished data). 
 Meta-structural data of the cBASP1 protein predicts a peptide comprising amino acid 
residues 60-80 with a high probability for protein interaction – probably with an extended 
or β-stranded part of a protein (Fig. 9) 
 A synthetical cell penetrating peptide comprising cBASP1 residues 60-80 C-terminally to 
a peptide stretch enabling penetration of the cell membrane (GRKKRRQRRR-G-
KVEKDAQVSANKTEEKEGEKE) lead to a cytopathic effect in MC29 transformed 
CEF, which is not observed with a control cell penetrating peptide harbouring cBASP1 
residues 15-30 (GRKKRRQRRR-G-NDEKAKDKDKKAEGAA) and a random control 
peptide lacking a cell penetration sequence (unpublished data). 
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 The cytopathic effect induced by the noted cBASP1 cell penetrating peptide is less 
stringent in untransformed CEF (unpublished data). 
 The transactivation domain (TAD) of c-Myc has already been shown to be bound and 
thereby regulated by different proteins (TRRAP, P-TEFb, NF-Y, MM1, TBP, Bin1,…) 
[64]. 
 The TAD of c-Myc, despite being mostly unfolded, was predicted by secondary structure 
prediction software (DSC, PHD and PREDATOR) to contain α-helical stretches, as well 
as β-stranded regions. Two of the predicted α-helices lie – at least partly – in Myc box I 
(MBI) and Myc box II (MBII), the regions described to be essential for binding of c-Myc 
TAD to other proteins [145]. On the contrary, Phe104 of rat B-Myc (corresponding to 
Phe115 of human c-Myc) seems to be involved in interaction with MM1 [151] and lies in 
a region predicted to be a β-strand [145]. 
 
 
 
Fig. 9. Residue-based Probability for Protein Interaction (PPI) and probable Secondary Structure of the 
Interactor (2nd IA) based on the Meta-structure analysis of chicken BASP1 (cBASP1). Ad 2nd IA: 
Probabilities for α-helical segments are typically below -100 (dashed line); probabilities for extended 
conformations and β-strands are typically above -100. The cBASP1 peptide (residues 60-80) is indicated by a 
grey box. 
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1. Construction of expression plasmids encoding His6-Carrier-
cBASP1pep 
 
A possibility by means of testing the interaction between the cBASP1 peptide 
(residues 60-80) and c-Myc is the pull-down technique. We decided to try out a His6 pull-
down method in combination with Ni2+ (or Co2+) affinity columns.  
Expression vectors were constructed encoding an N-terminally His6 tagged version of 
the cBASP1 peptide including a Carrier protein for solubility reasons and a TEV cleavage site 
between the Carrier and the N-terminal cBASP1 peptide to allow cleavage of the peptide from 
the His6-Carrier moiety. Fig. 10 shows a schematic representation of the 5 different encoded 
His6-‘Ca’-cBASP1 peptide fusion proteins. Construction of the pET-His6-‘Ca’-cBASP1pep 
expression vectors and properties of the different carrier proteins are described in section: 
“Construction of expression vectors coding for His6-Carrier-cBASP1 peptide fusion 
protein”.  
 
 
MKHHHHHHPMSD..trx-carrier...NLAGSGSGSENLYFQ‘GAMEKVEKDAQVSANKTEEKEGEKE
MKHHHHHHPMKQ..GB1-carrier...VTEGSGSGSENLYFQ‘GAMEKVEKDAQVSANKTEEKEGEKE
MKHHHHHHPMKE..NusA-carrier..EATGSGSGSENLYFQ‘GAMEKVEKDAQVSANKTEEKEGEKE
MKHHHHHHPMKQ..Z2-carrier....VDAGSGSGSENLYFQ‘GAMEKVEKDAQVSANKTEEKEGEKE
11.5 kDa
12.9 kDa
16.96 kDa
45.7 kDa
60.0 kDa
MKHHHHHHPMKI..MBP-carrier...TNSGSGSGSENLYFQ‘GAMEKVEKDAQVSANKTEEKEGEKE
 
 
 
 
 
2. The His6-Carrier-cBASP1 peptide fusion proteins 
 
As described in section “Expression and Purification of His6-Carrier-cBASP1 peptide 
fusion proteins”, the different fusion proteins were expressed in the E.coli strain 
Rosetta(DE3)pLysS and purified via Ni2+ affinity chromatography and optional preparative 
gel filtration (Fig. 11). The molecular weights of the individual His6-‘Ca’-cBASP1pep fusion 
Fig. 10. Schematic representation of the His6-‘Ca‘-cBASP1pep fusion proteins. His6 tag and Carrier proteins 
in green; TEV protease recognition site with the site of cleavage in red; cBASP1 peptide sequence 
(corresponding to cBASP1 residues 59-80) in blue. Identical regions are marked by grey boxes. 
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proteins as well as the apparent molecular weights at which the individual proteins are 
migrating on a 15% SDS polyacrylamide gel are noted in the table below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MW (kDa) Apparent MW (kDa) 
His6-GB1-cBASP1pep 11.5 ~ 17.5 * 
His6-MBP-cBASP1pep 45.7 ~ 45 
His6-NusA-cBASP1pep 60.0 ~ 66 
His6-trx-cBASP1pep 16.96 ~ 18 
His6-Z2-cBASP1pep 12.9 ~ 16 
*His6-GB1-cBASP1pep sometimes didn’t migrate properly and produced long smears 
on a 15 % SDS-polyacrylamide gel 
Fig. 11. Purified His6-‘Ca‘-cBASP1pep fusion proteins. Coomassie stained 15% SDS-polyacrylamide gels 
show pure fractions of recombinant protein after Ni2+ affinity chromatography or after an additional 
preparative gel filtration step. 
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In order to test the possibility for cleavage with TEV protease, an initial screen for 
TEV protease – substrate ratio determination was performed on His6-trx-cBASP1pep as 
described in section “TEV protease cleavage of proteins”. Aliquots of the different cleavage 
mixtures were analyzed by SDS-PAGE (Fig. 12). Cleavage of the cBASP1 peptide from the 
His6-trx moiety had been in principle successful confirming the functionality of the TEV 
cleavage site. His6-trx-cBASP1pep (16.96 kDa) migrates at ~ 18 kDa, whereas the cleaved 
fragment His6-trx (14.2 kDa) migrates at ~ 14.4 kDa. The cleaved cBASP1 peptide (GAM-
EKVEKDAQVSANKTEEKEGEKE) with a molecular weight of 2765 Da can’t be seen on 
the SDS-polyacrylamide gel, as peptides smaller then 5 kDa can diffuse out of the gel during 
the staining procedure. Even at a ratio 1:50 of TEV protease to His6-trx-cBASP1pep only half 
the amount of protein was cleaved. There are different explanations for the low processing 
efficiency. Firstly, the sample of TEV protease is already old and therefore TEV protease 
activity is reduced. Also autolysis of TEV protease has been described, which renders the 
protease inactive [176]. Secondly, steric hindrance at the TEV cleavage site might be a reason 
for low activity. 
 
 
 
 
 
 
 
  
 
Fig. 12. TEV cleavage of His6-trx-cBASP1pep. Lanes 2-9 show different ratios of TEV protease to His6-trx-
cBASP1pep and different amounts of protein applied onto the SDS polyacrylamide gel. As a control served 2 
µg of full length His6-trx-cBASP1pep (lane 1). Full length His6-trx-cBASP1pep (16.96 kDa) migrates at ~ 18 
kDa. Cleaved His6-trx (14.2 kDa)  migrates at ~ 14.4 kDa.  
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3. The MC29EB protein 
 
The cBASP1 peptide was hypothesized to interact with the transactivation domain of 
c-Myc. The MC29EB protein encoded by pET3d-MC29EB corresponds to a part of the viral 
Gag-Myc fusion protein, which comprises v-Myc residues 1-140 corresponding to chicken c-
Myc TAD (residues 1-140) with additional 14 N-terminal residues from the viral Gag protein 
and 6 residues encoded by the 5’ untranslated region of chicken c-Myc. Fig. 13 (A) shows a 
schematic representation of the MC29 retrovirus encoded Gag-Myc fusion protein, the 
recombinant MC29EB protein and chicken c-Myc. The term v-Myc corresponds to the part of 
the Gag-Myc fusion protein, which was derived from the cellular proto-oncogenic c-Myc 
sequence. Several substitution mutations of key residues are found in the MC29 encoded v-
Myc sequence, which are noted in the table below. 
 
 human c-Myc chicken c-Myc  MC29 Gag-Myc 
phosphorylation site and O-GlcNAc 
glycosylation site [78] Thr58 Thr61 → Met61 
acetylation site [180, 181] Lys157 Arg146 → Gln146 
phosphorylation site [182] Ser348 Ser325 → Leu325 
phosphorylation site [183] Ser373 Ser350 → Arg350 
not determined Lys430 Lys407 → Asn407 
 
 
MC29EB was expressed in the E.coli strain Rosetta(DE3)pLysS, enriched from 
inclusion bodies and depending on subsequent experiments, purified via anion exchange 
chromatography under denaturing conditions and preparative gel filtration as described in 
section “Expression and purification of the MC29EB protein”. Preparative gel filtration was 
carried out after dialysis and renaturation of MC29EB in 20 mM Tris×HCl pH 7.4. MC29EB 
was eluted in all protein containing fractions (Fig. 13, B). A contaminating protein migrating 
at ~ 26 kDa was even eluted in the purest fractions after preparative gel filtration and could 
not be removed by gel filtration under denaturing conditions (data not shown).  
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Fig. 13. MC29EB recombinant protein. (A) Schematic representation of the Gag-Myc fusion protein encoded 
by the MC29 retrovirus, the MC29EB recombinant protein and chicken c-Myc. Gag (grey); TAD: 
transactivation domain (yellow); MB I-III: Myc boxes I-III (red); bHLHZip motif (light blue); peptide 
encoded by the 5’ untranslated region of chicken c-Myc (blue); substitution mutations (arrowheads). Grey 
numbers correspond to MC29 Gag protein. Black numbers correspond to chicken c-Myc. The extended 
bracket indicating TAD reminds for the recent finding that a C-terminally prolonged region of TAD is 
binding with higher affinity to interactors than the previously described “minimal region” of TAD. 
(B) Preparative gel filtration of MC29EB in 20 mM Tris×HCl (pH 7.4) after anion exchange chromatography 
under denaturing conditions. The Coomassie stained 15% SDS-polyacrylamide gel shows protein containing 
fractions. MC29EB (17.8 kDa) migrates at ~ 21 kDa. Compare impure fractions (lanes 1-4) with more or less 
pure fractions (lanes 5-8). 
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4. Circular Dichroism Spectroscopy of MC29EB 
 
CD measurement has been performed to estimate the secondary structural content of 
MC29EB protein. The CD spectrum of MC29EB shows the characteristics of a random 
conformation with a minimum at around 200 nm (Fig. 14). Similar spectra were observed 
with a human c-Myc TAD polypeptide spanning residues 1-143 (human c-Myc1-143) [149]. 
CD measurements with a slightly extended version of human c-Myc TAD (c-Myc1-167) show a 
shift of the minimum from 200 nm towards 208 nm and an increased negative CD signal at 
222 nm, which is characteristic for α-helical structures [145]. Interestingly, a similar increase 
in α-helical structure has been observed with c-Myc1-143 after addition of the hydrophobic 
solvent TFE (trifluoroethanol), which favours secondary structure formation in regions which 
have a propensity to form an α-helix [149]. The MC29EB CD spectrum, compared with 
spectra observed with human c-Myc1-143 before and after addition of 10% TFE [149] as well 
as with spectra observed with human c-Myc1-167 [145], might already show some contribution 
of α-helical structure deduced from the slight dip in the curve at around 222 nm. As a matter 
of fact, MC29EB comprises residues 1-140 of chicken c-Myc and residue 140 from chicken c-
Myc is equivalent to residue 151 of human c-Myc. It therefore extends further into a region, 
which is described to enhance α-helical structure formation.  
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Fig. 14. Far-ultraviolet circular dichroism spectrum of MC29EB in NaP buffer (20 mM sodium phosphate pH 
7.4). Ellipticity in mdeg is plotted as a function of wavelength in nm (at 23.4°C). 
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5. Pull-down assay with purified His6-Carrier-cBASP1pep as 
bait protein and enriched MC29EB as prey protein 
 
We wanted to investigate the formation of a complex between a His6-‘Ca’-
cBASP1pep fusion protein and MC29EB by using a pull-down methodology. In an on-
column binding assay, we loaded His6-MBP-cBASP1pep onto a Ni2+-column, washed with 
low imidazole buffer and loaded MC29EB onto the His6-MBP-cBASP1pep charged Ni2+ 
column at very slow flow rates. MC29EB was eluted during the loading and the subsequent 
washing step. His6-MBP-cBASP1pep was eluted without bound MC29EB during the 
following gradient elution. Protein containing fractions after gradient elution were pooled and 
loaded onto a gel filtration column. Protein containing fractions after gel filtration were 
analyzed by SDS-PAGE. 
It seems that MC29EB is not binding to His6-MBP-cBASP1pep as it is already eluted 
during the loading step (Fig. 15, A). SDS-PAGE of the flow-through fraction confirmed that 
the peak corresponds to MC29EB (data not shown). Subsequent gradient elution, gel filtration 
and SDS-PAGE seem to confirm that MC29EB does not bind to His6-MBP-cBASP1pep (Fig. 
15, B-D). 
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In order to test, if the on-column binding method might be the reason for the failure of 
complex formation, as the continuous flow during loading and washing steps might hinder 
interaction between MC29EB and His6-MBP-cBASP1pep, we mixed the potential binding 
partners before loading them onto the Ni2+ column. In this experiment His6-trx-cBASP1pep 
was used as a bait protein. MC29EB was mixed with an excess of His6-trx-cBASP1pep and 
incubated for 1 h at 4°C. Afterwards the mixture was divided into 4 aliquots. The aliquots 
were incubated 0 min, 1 min, 5 min and 10 min at 37°C, respectively. Each mixture was 
loaded onto a Ni2+-column. In all four pull-down assays MC29EB was eluted during the 
loading and washing steps (Fig. 16, compare A and B with lane 1 in D). During the 
subsequent gradient elution only His6-trx-cBASP1pep protein was eluted (Fig. 16, compare C 
with lane 2-5 in D). The flow-through fractions as well as protein containing fractions during 
the gradient elution were analyzed by SDS-PAGE (Fig. 16, D). The chromatograms and the 
SDS polyacrylamide gel are shown for the sample, which was incubated for 5 min at 37°C. 
The other 3 samples produced similar results (data not shown).  
Hence, complex formation between the tagged cBASP1 peptide and MC29EB could 
not be observed with the pull-down method in combination with Ni2+ columns. 
Fig. 15. On-column binding assay with His6-MBP-cBASP1pep and MC29EB. (A) Chromatogram after 
loading MC29EB onto the His6-MBP-cBASP1pep charged Ni2+ column. (B) Chromatogram of the 
subsequent gradient elution from 0-100% high imidazole buffer. (C) Gel filtration of protein containing 
fractions after gradient elution. (D) SDS-polyacrylamide gel of protein containing fractions after gel filtration. 
Numbering of lanes (1-7) corresponds to the fractions denoted in the chromatogram of the gel filtration step. 
His6-MBP-cBASP1pep migrates at ~ 45 kDa. MC29EB migrates at ~ 21 kDa. 
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Fig. 16. Pull-down assay with His6-trx-
cBASP1pep and MC29EB. (A-C) 
Chromatograms corresponding to different 
steps during the pull-down assay. (A) 
Loading the mixture of His6-trx-
cBASP1pep and MC29EB onto the Ni2+ 
column. (B) Washing step with low 
imidazole buffer. (C) Gradient elution 
from 0-100% high imidazole buffer. (D) 
SDS-PAGE of protein containing 
fractions after gradient elution from Ni2+ 
column. Numbering of lanes 2-5 (1-3) 
corresponds to the fractions denoted in the 
chromatogram of the gradient elution step. 
MC29EB migrates at ~ 21 kDa. His6-trx-
cBASP1pep migrates at ~ 18 kDa. 
 
 
 93 
6. Binding assay between His6-Carrier-cBASP1pep and 
MC29EB via analytical gel filtration  
 
Another method to investigate complex formation between proteins is analytical size 
exclusion chromatography (Superdex 75 10/300 GL). If two proteins form a complex, the 
complex can be observed at an elution volume distinct from the elution volumes of the single 
proteins.  
In this experiment, His6-GB1-cBASP1pep was used as potential interactor. First, the 
single components of the potential complex were applied to analytical gel filtration with the 
elution volumes 9.05 ml (Kav = 0.068) for MC29EB (17.8 kDa) (Fig. 17, A) and 10.29 ml (Kav 
= 0.147) for His6-GB1-cBASP1pep (11.5 kDa) (Fig. 17, B). An equimolar mixture of the two 
proteins incubated for ~ 1 h at 4°C produced a chromatogram with two peaks at the elution 
volumes 8.76 ml (Kav = 0.049) and 10.16 ml (Kav = 0.139) (Fig. 17, C).  
As a matter of fact no run with standard proteins was performed, so conclusions about 
multimeric states or the migration at the correct elution volume according to the size of the 
analyzed protein cannot be drawn. Despite those facts, the elution volumes of the two peaks 
observed during analytical gel filtration with the mixture of proteins nearly correspond to the 
elution volumes that were observed with the individual components. This interpretation 
favours the observation of no complex formation between the two proteins and is in 
accordance with previous results.  
Another possible interpretation relies on the assumption that the peak at the elution 
volume of 8.76 ml does not correspond to the peak of single MC29EB at the elution volume 
of 9.05 ml. Accordingly, the mentioned peak at 8.76 ml would correspond to a complex 
between His6-GB1-cBASP1pep and MC29EB. The peak at an elution volume of 10.16 ml 
would then correspond to excess unbound His6-GB1-cBASP1pep protein. Contradicting this 
theory is the assumption that a complex between His6-GB1-cBASP1pep and MC29EB with a 
molecular weight of ~ 29.3 kDa would have a lower elution volume than 8.76 ml. 
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Fig. 17. Binding assay between His6-GB1-cBASP1pep and MC29EB via analytical gel filtration. (A) 
MC29EB alone with an elution volume of 9.05 ml. (B) His6-GB1-cBASP1pep alone with an elution volume 
of 10.29 ml. (C) Equimolar mixture of His6-GB1-cBASP1pep and MC29EB. Two peaks with elution 
volumes 8.76 ml and 10.16 ml. 
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Investigation of direct interaction between v-Myc 
and the cBASP1 interacting peptide 
 
 
1. MC29 transformed chicken embryonic fibroblasts 
 
Previous pull-down assays were performed with MC29EB, which is an N- and C-
terminally truncated version of the MC29 Gag-Myc fusion protein (v-Myc), therefore being 
devoid of C-terminal regions corresponding to chicken c-Myc (residues 141-416). In order to 
test if full length v-Myc may bind to His6-Carrier-cBASP1pep fusion proteins, we wanted to 
perform a pull-down assay with His6-Carrier-cBASP1pep (bait protein) and cellular extracts 
from MC29 transformed chicken embryonic fibroblasts, which express oncogenic v-Myc. 
Chicken embryonic fibroblasts were transformed with MC29 virus and after adopting 
a transformed state (visual inspection) cellular extracts were harvested and prepared for 
subsequent pull-down assays. 
 
 
2. Pull-down assay with purified His6-Carrier-cBASP1pep as 
bait protein and cellular extract from MC29 transformed CEF 
 
Pull-down assays with His6-trx-cBASP1pep and cellular extract from MC29 
transformed CEF were performed as described in section “Pull-Down Assay” on HiTrap 
Chelating HP 1ml columns with Co2+ as the immobilized metal ion. Co2+ has been observed 
to be less susceptible to unspecific binding of proteins. Eluted fractions were subsequently 
analyzed by SDS-PAGE and western blot analysis using antibodies directed against v-Myc 
and antibodies directed against WS5 as a control. WS5 is a gene differentially expressed in 
transformed fibroblasts and is not supposed to interact with cBASP1. 
Pre-clearing of the cellular extract and pull down assays were performed with buffers 
supplemented with 0.5 M NaCl to reduce unspecific binding of proteins to the Co2+ column. 
Nonetheless, at the pre-clearing step it can be seen that v-Myc binds unspecificaly to the Co2+ 
column. It is eluted in the pre-cleared fraction as well as in the fraction containing non-
specific binders (Fig. 18, compare lanes 2 and 3). Therefore, it is hard to draw conclusions 
regarding interaction between v-Myc and His6-trx-cBASP1pep. In the pull-down assay 
without pre-clearing of the cellular extract, v-Myc is mainly eluted during elution with high 
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imidazole but is also found in the flow through fraction (Fig. 18, compare lane 8 with lane 7). 
Interestingly, in the same assay even WS5, which is not supposed to bind to cBASP1, is 
eluted during the elution with high imidazole (Fig. 18, lane 8, lower panel). The pull-down 
assay performed with pre-cleared cellular extract is inconclusive as well. As before, v-Myc is 
found in the flow-through fraction and in the elution fraction (Fig. 18, lanes 4 and 5). Bands 
are less strong as compared to bands observed during the pull-down assay without pre-
clearing of the cellular extract, as already a lot of v-Myc protein is lost during the pre-clearing 
step. 
 
 
 
 
 
Other pull-down assays performed, included a pull-down assay with His6-trx-
cBASP1pep and cellular extracts from untransformed quail embryonic fibroblasts in order to 
investigate direct interaction between His6-trx-cBASP1pep and endogenous c-Myc. Despite 
the fact that antibodies directed against chicken c-Myc also recognize quail c-Myc, the 
outcome of the pull-down is inconclusive. Bands corresponding to chicken c-Myc and quail c-
Myc, respectively, could only be observed in lanes, where 12.4 µg of MC29 transformed CEF 
cell extract and 9 µg of untransformed QEF cell extract was loaded onto the SDS-
polyacrylamide gel (data not shown). 
Fig. 18. Pull-down assay with His6-trx-cBASP1pep and cellular extract from MC29 transformed chicken 
embryonic fibroblasts (CEF) and subsequent Western blot analysis with antibodies directed against Myc 
(upper panel) and antibodies directed against WS5 as a control (lower panel). Pull-downs were performed 
either directly with cellular extract (6.2 mg) or after pre-clearing of cellular extract (6.2 mg). Samples were 
fractionated over a Co2+ column (HiTrap Chelating HP 1 ml) loaded with ~ 1 mg of His6-trx-cBASP1pep. CE 
(cellular extract); CE_PC (pre-cleared cellular extract); CE_NS (non-specific binders of the Co2+ column 
within the cellular extract); PD_FT (flow through fraction of the pull-down); PD elute (eluted fractions of the 
pull-down).  
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A pull-down assay, intended as a control for a specific interaction of Myc, was carried 
out with a His6 tagged version of the Minimax protein (His6-Minimax → section: 
“Expression and purification of His6-Minimax”) and cellular extract from MC29 transformed 
CEF. In this experiment, pre-clearing was not performed. v-Myc is found in the flow-through 
fraction, what is particular disturbing as it should specifically interact with Minimax, and in 
the elution fractions of the pull-down (data not shown). Here has to be mentioned, that His6-
Minimax behaved strangely during purification by Ni2+ affinity chromatography. Only about 
50% of the recombinant protein was retained by the Ni2+ column. It might be that the ability 
of Max to form homodimers interferes with the ability to bind to the Ni2+ column. This might 
also serve as an explanation why v-Myc is partly found in the flow through fraction. Binding 
of v-Myc to His6-Minimax might interfere with binding of the His6 tag to the Co2+ column; 
consequently v-Myc would strip His6-Minimax from the Co2+ column. 
 
Concluding, it is presumed that positive results of the performed pull-down assays are 
mainly due to unspecific binding of proteins to the Co2+ column. Hence, complex formation 
between v-Myc or c-Myc and the His6-‘Ca’-cBASP1pep fusion proteins used in this study 
cannot be confirmed with the pull-down method in combination with Co2+ or Ni2+ columns. 
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Meta-structure analysis of BASP1 and WT1 
 
Human BASP1 has been identified as cosuppressor of human WT1 via binding to the 
WT1 suppression region (WT1 residues 92-101) [161]. We wanted to test, if meta-structure 
analysis of those proteins is in agreement with those findings. Meta-structure analysis of 
proteins predicts residue-based compactness and secondary structure of a protein. Meta-
structural parameters are then used to predict residue-based protein interaction probabilities as 
well as the probable secondary structure of the interactor. 
Protein alignment of human BASP1 and chicken BASP1 indicates 63.1% sequence 
identity between those proteins. Fig. 19 shows an alignment (ClustalW) of BASP1 from 
different species. The N-terminus is highly conserved in different species, highlighting its 
importance for BASP1 function. As a matter of fact, interaction with CaM depends on 
residues at the extreme N-terminus of BASP1 and the myristoyl-group, which is attached to 
the N-terminus of BASP1 [169]. Myristoylation is not found with BASP1 functioning as a 
transcriptional cosuppressor [161]. The region around chicken BASP1 residues 60-80 is less 
conserved between different species. Meta-structure analysis of chicken BASP1 and human 
BASP1 depicts a similar low degree of compactness and secondary structural content (→ 
“Introduction” Fig. 7) for compactness and secondary structure prediction of chicken BASP1) 
and more importantly, a quite similar profile concerning probability for protein interaction 
(Fig. 20); highest probabilities were predicted for chicken BASP1 residues 42-80 and for 
human BASP1 residues 42-90, despite the relatively low degree of conservation in those 
regions. The low probability values calculated for human BASP1 residues 68-84 are possibly 
due to technical reasons of the alignment algorithm used. As the N-terminal myristoyl-group 
is indispensable for interaction of BASP1 with CaM, the meta-structure analysis does not 
predict high probability for protein interaction for the N-terminus of BASP1. For chicken 
BASP1 the secondary structure of the interactor was predicted to be in an extended, loop or β-
stranded conformation. 
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Fig. 19. Alignment of BASP1 amino acid sequences from different species. The colour code outlines roughly amino acid properties: acidic (blue), basic (red), hydrophobic (green), 
polar (yellow) as well as cysteine (orange) and proline (grey). The histogram bellow gives a measure of conservation between the sequences of the different species. The red box 
indicates the region of chicken BASP1 (residues 60-80), which is predicted to have a high probability for protein interaction and which was used for pull-down experiments. Upper 
numbers correspond to human BASP1 residue numbers. 
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Fig. 21 shows a protein alignment (ClustalW) of human WT1 isoform C and chicken 
WT1 (87.3% sequence identity). Even between chicken and humans, WT1 amino acid 
sequence is well conserved, especially in the C-terminus harbouring the four zinc-fingers 
necessary for DNA binding. Meta-structure analysis of human WT1 and chicken WT1 
predicted similar values of high compactness and predominantly β-strand secondary structural 
elements. Fig. 22 shows compactness and secondary structure prediction for human WT1 
isoform C. The N-terminal suppression region of WT1 spanning residues 92-101 (indicated 
by the grey box in Fig. 21 and Fig. 22) is predicted to be in a loop or β-stranded 
conformation. This finding is consistent with the prediction of the secondary structure of the 
BASP1 interactor, which was also predicted to be in a loop or β-stranded conformation.  
Fig. 20. Residue-based Probability for Protein Interaction (PPI) based on the meta-structure analysis of 
human BASP1 and chicken BASP1 as well as probable Secondary Structure of the Interactor (2nd IA) of 
chicken BASP1. Ad 2nd IA: Probabilities for α-helical segments are typically below -100 (dashed line); 
probabilities for extended conformations and β-strands are typically above -100. Regions with high 
probability for interaction are indicated by orange boxes. The cBASP1 peptide (residues 60-80) is indicated 
by a grey box.  
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Fig. 21. Alignment of human WT1isoform C and chicken WT1 amino acid sequences. The colour code outlines roughly amino acid properties: acidic (blue), basic (red), 
hydrophobic (green), polar (yellow) as well as cysteine (orange) and proline (grey). The histogram bellow gives a measure of conservation between the different sequences. 
The grey box indicates the suppression region of WT1 (human WT1 residues 92-101). Upper numbers correspond to human WT1 residue numbers. 
 
 
Fig. 23 shows the meta-structure based analysis of probability for protein interaction and 
secondary structure of the interactor of human WT1, which is similar to chicken WT1. It 
depicts a very high probability for interaction in three large parts of the protein. An N-
terminal region of high interaction probability (residues 70-106), which surrounds the 
suppression domain (residues 92-101), a part in the middle with high interaction probability 
(residues 153-245), which coincides with the transactivation domain of WT1 (residues 180-
250) [161] and a C-terminal region of high interaction probability (residues 292-435), where 
the C-terminal zinc-fingers are located. For the suppression region the secondary structure of 
the interactor is predicted to be rather in a loop or β-stranded conformation. 
 
 
 
Fig. 22. Meta-structure analysis of human WT1 isoform C yielding residue-based Compactness values and 
Secondary Structure probabilities. Probabilities for α-helical segments are typically above 100 (dashed line); 
probabilities for extended conformations and β-strands are typically below 100. The N-terminal suppression 
region is indicated by a grey box. 
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The finding that the interactor of the WT1 suppression region is in a rather loop or β-
stranded conformation is consistent with the meta-structural data of chicken BASP1 (→ 
“Introduction” Fig. 7). Meta-structure analysis of human BASP1 in the region of high protein 
interaction probability predicts also a propensity for the formation of α-helical segments, 
especially the region spanning residues 73-80 (Fig. 24).  
Fig. 23. Residue-based Probability for Protein Interaction (PPI) as well as probable Secondary Structure of 
the Interactor (2nd IA) of human WT1 isoform C based on its meta-structure analysis. Ad 2nd IA: 
Probabilities for α-helical segments are typically below -100 (dashed line); probabilities for extended 
conformations and β-strands are typically above -100. Regions with high probability for interaction are 
indicated by orange boxes. The WT1 suppression region is indicated by a grey box.  
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Concluding, meta-structure analysis of WT1 and BASP1 supports the finding that 
BASP1 interacts via a region found to be highly probable for protein interaction with the 
suppression region of WT1. 
 
 
 
 
Fig. 24. Meta-structure analysis of human BASP1 yielding residue-based Compactness values and Secondary 
Structure probabilities as well as Probabilities for Protein Interaction (PPI). Ad Secondary Structure 
prediction: probabilities for α-helical segments are typically above 100 (dashed line); probabilities for 
extended conformations and β-strands are typically below 100. The region with highest probability for protein 
interaction is indicated by an orange box (residues 42-80).  
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Discussion 
 
 
The Pull-down assay as a method for the 
investigation of protein interaction 
 
The pull-down assay is a quite powerful tool in confirming the interaction between 
proteins and is comparable to immunoprecipitation techniques. But it has to be handled with 
great care and it cannot – as can be seen by the difficulties encountered in this study – be used 
as the sole experiment to verify a potential protein interaction. As a matter of fact, positive 
results don’t mean necessarily direct interaction between two proteins. A lot of proteins may 
exist in multi-protein complexes and a seemingly direct interaction could also be explained by 
indirect interaction via adaptor proteins, which tether two proteins together. Other methods 
exist to validate direct interaction of proteins. 
Pull-down assays are usually performed with GST tags on glutathione agarose or His6 
tags in combination with immobilized bivalent metal ion matrices. GST tags should be 
favoured in the sense that they are less prone to unspecific binding of proteins to the affinity 
ligand. A lot of proteins are able to bind bivalent ions by themselves and therefore might bind 
unwanted to the immobilized metal ions used with the His6 methodology. Furthermore ion 
exchange effects are observed with IMAC columns. Therefore, especially with very acidic 
proteins, it is not advisable to use pull down techniques based on IMAC. 
As a matter of fact, MC29EB, c-Myc and v-Myc are quite acidic proteins with 
theoretical pI values of 4.33, 5.28 and 5.52, respectively. Anion exchange chromatography 
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even is used for the purification of MC29EB. So it is not quite surprising that ion exchange 
effects are observed with those proteins in combination with Ni2+/Co2+ columns. On the other 
hand, unspecific binding to the column could not be observed during pull-down assays 
performed with purified MC29EB. However, in this case Coomassie Staining of 
polyacrylamide gels was used to detect the proteins in question, which is a highly insensitive 
detection method. Therefore it is possible that minimal undetectable amounts of MC29EB 
adhered unspecificaly to the Ni2+ column. The immunoblotting method used for detection of 
v-Myc or endogenous c-Myc in cellular extracts is much more sensitive and therefore able to 
detect small amounts of unspecificaly bound proteins.  
To produce reliable results, it is important to include negative and positive controls. 
As positive control a protein should be used, which has been already confirmed to interact 
with the BASP1 protein (e.g. WT1). BASP1 was identified as cosuppressor for the Wilms’ 
tumor suppressor protein 1 (WT1) and has been shown with the help of pull-down assays to 
interact with an N-terminal suppression region of WT1 [161]. Additionally, it would be 
advisable to test full-length BASP1 for binding to target proteins in advance. As negative 
control has to be used the tag alone bound to the column. In the current study the His6-‘Ca’ 
moiety without the C-terminal cBASP1 peptide would serve as a negative control. 
 
 
Does BASP1 bind directly to Myc TAD? 
 
In the current study the N-terminal transactivation domain of chicken c-Myc and v-
Myc, respectively, wanted to be tested for interaction with cBASP1. Therefore, His6 tagged 
fusion proteins were expressed and purified, which contain a small peptide stretch of cBASP1 
(residues 59 to 80). The meta-structure approach predicted this peptide to be highly probable 
for interaction with a supposably loop or β-stranded part of another protein. In subsequent 
pull-down assays the fusion proteins were used as bait proteins and either a purified part of v-
Myc containing chicken c-Myc TAD residues 1-140 (MC29EB) or full-length v-Myc 
(cellular lysate from MC29 transformed chicken embryonic fibroblasts) and/or endogenous c-
Myc (cellular lysate from untransformed chicken embryonic fibroblasts) as potential prey 
proteins. There are different possibilities to explain the failure to observe direct interaction 
between those proteins. 
First of all, we didn’t test full length cBASP1 for interaction with Myc TAD. High 
affinity binding of cBASP1 to Myc might need a bigger portion of the protein compared to 
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the 20 residues peptide used in this study. Moreover, the carrier protein fused to the small 
cBASP1 peptide might interfere with the capacity of the peptide to bind to other proteins. A 
possibility to test for those factors, the already described BASP1 interactor WT1 or its 
suppression domain ranging from WT1 residue 92-101 [161] should be tested for interaction 
with the Carrier-BASP1-peptide fusion proteins. Even so, a negative result will not solve the 
problem, if the carrier might disturb interaction or the peptide is too short for high affinity 
binding. 
Furthermore and worth to notice, is the recent finding that residues 1-143 of Myc 
TAD are less efficiently binding to Myc interacting proteins MM1 and TBP as compared to a 
more elongated Myc TAD (human c-Myc1-167) [145]. Maybe binding of BASP1 is even not 
possible with the shorter version of c-Myc TAD. In the referred study a more elongated 
region, including Myc residues 144-167, was discovered to greatly enhance binding to the 
mentioned interactors [145]. Human c-Myc residues 1-143 were formerly described as being 
the minimal region required for neoplastic transformation of primary rat embryo cells in 
cooperation with oncogenic Ras [148]. Even though, nearly devoid of secondary structure – 
rather adopting a random coil conformation –, c-Myc1-143 is still able to interact with TBP. 
Moreover, an induction of protein conformation could be seen with c-Myc1-143 upon binding 
to the target factor TBP [149]. Interestingly, secondary structure prediction software predicted 
an amphipathic helix ranging from human c-Myc residues 140-157. As a matter of fact, CD 
measurements of human c-Myc1-167 show a higher degree of helicity as c-Myc1-143 and 
indicate a molten globule-like state of c-Myc1-167 as compared to the random coil 
conformation of c-Myc1-143 [145, 149]. At this point, it is notable that studies concerned with 
c-Myc degradation gave contradictory results, if fusion proteins were attached to the N-
terminus of a c-Myc TAD 1-147 construct [184] or to the C-terminus of a c-Myc TAD 1-149 
construct [185]. C-terminal fusion proteins may stabilize c-Myc TAD in the sense that they 
could induce protein conformation in a similar way as c-Myc residues 144-167 do, which 
harbour the predicted amphipathic helix. Conversely, a c-Myc TAD 1-147 construct with an 
N-terminal fusion protein might miss the induction of protein conformation and therefore is 
more prone to protein degradation. 
Secondary structure prediction of human c-Myc TAD suggested α-helical as well as 
β-stranded parts, which are outlined in Fig. 6 in the introduction. Three β-strands were 
predicted covering residues 3-7, 22-24 and 114-116. Four α-helices were identified spanning 
residues 31-37, 47-53, 96-106 and 140-157, where the latter three are supposably amphipathic 
[145]. Binding of proteins to c-Myc TAD can be quite diverse. For example, cyclin T1 
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binding to Myc was identified to depend on the highly conserved Myc box I, whereas cdk8 
binding localized to the extreme N-terminus of the Myc TAD [186], where rather β-stranded 
parts were predicted. Interaction studies using B-Myc revealed that MM-1 binding to B-Myc 
affects Myc box I and Myc box II as well as residues found outside the conserved Myc boxes. 
One of those residues Phe104 of rat B-Myc (corresponding to Phe115 of human c-Myc) even 
lies in a supposably β-stranded region of human c-Myc TAD (residues 114-116). Association 
of TBP with B-Myc influences mostly Myc box II and sequences C-terminal to this core 
motif [151]. Interestingly, studies elucidating the interaction mechanism of Myc TAD with 
TBP and MM-1, respectively, with the help of surface plasmon resonance assays employing 
Biacore technology as well as CD spectroscopy, revealed that the N-terminal part of c-Myc 
TAD alone (c-Myc1-88) is not able to bind TBP and MM-1, whereas the C-terminal part (c-
Myc92-167) binds TBP and MM-1 but with less affinity as compared with c-Myc1-167 and c-
Myc38-167. Only the full-length TAD (c-Myc1-167) binds TBP and MM-1 with highest affinity. 
Therefore it was concluded, that N- and C-terminal halves cooperate in binding to target 
proteins. The kinetic data of interaction between Myc and TBP or MM-1 was found to fit a 
conformational change model, where binding to interactors enhances helicity indicating a 
possible folding-upon-binding mechanism. The additional stretch of residues 144-167 is 
needed for stabilizing secondary structures and for high affinity binding to interactors [145].  
BASP1 has been predicted by the meta-structure approach to bind to a rather loop or 
β-stranded entity of a protein. As binding of proteins to Myc TAD can involve quite different 
parts of the transactivation domain, it might be possible that binding of BASP1 to Myc TAD 
depends strongly on the predicted α-helical stretch reaching from human c-Myc residues 140-
157 to induce protein conformation and thereby establishing the interaction platform for 
BASP1. In our study we used the recombinant protein MC29EB as a potential interactor of 
chicken BASP1 (cBASP1). MC29EB harbours residues 1-140 of chicken c-Myc TAD, which 
correspond to residues 1-151 of human c-Myc. Therefore MC29EB ends in the middle of the 
region predicted to form an amphipathic α-helix. Hence, it’s quite possible that MC29EB is 
not able to form this C-terminal helix. CD measurements of MC29EB seem to support this 
view, as the spectra indicate a rather random coil conformation of MC29EB. Maybe BASP1 
needs a better folded part to be able to interact with Myc TAD. 
Another possibility is that BASP1 binds to the C-terminal bHLHZip domain of Myc. 
As a matter of fact, this region has been shown to be involved not only in dimer or possibly 
tetramer formation but also interacts with other proteins that regulate Myc function as CBP 
 109 
and p300 [112]. On the other hand, the C-terminus of c-Myc consists almost entirely of α-
helices and therefore is rather unlikely to interact with BASP1. 
 
 
 
The mutual suppression of Myc and BASP1  
 
Ectopic expression of BASP1 hinders transformation by v-Myc 
 
We wanted to investigate direct binding between Myc and BASP1 based on the 
observations outlined in the “Results”-section.  
Ectopic expression of cBASP1 in chicken embryonic fibroblasts hinders 
transformation by v-Myc (unpublished data). Direct binding between Myc and cBASP1 can 
be the reason for the inability of v-Myc to exert its oncogenic function in cBASP1 
overexpressing cells. cBASP1 might hinder v-Myc in exerting its function as a transcriptional 
activator by obstructing its ability to bind to its target genes. Nevertheless, this scenario is 
rather improbable as it would involve interaction of cBASP1 with the C-terminus of Myc. 
Another possibility involving direct interaction might be that BASP1 acts as a cosuppressor 
of Myc by binding to its transactivation domain, subsequently switching Myc function from 
an activating to a repressing state. Similarly, WT1 was discovered as a transcriptional 
activator, but represses transcription when in complex with BASP1 [161].  
Direct binding between Myc and BASP1 is only one possibility to explain the mutual 
suppression found with those two proteins. As quoted before, BASP1 is able to interact with 
WT1 and thereby leads to the repression of WT1 target genes. WT1 is a transcription factor 
that plays an essential role in urogenital development and it is overexpressed in a variety of 
human cancers. WT1 can bind via its four zinc fingers to GC-rich Egr1 sites (5’-
GNGNGGGNG-3’) [187], to WTE sites (5’-GCGTGGGAGT-3’) [188] and to the (TCC)n 
motif [189] and either enhances or represses transcription. Target genes of WT1 comprise 
growth factor genes, growth factor repressor genes, transcription factor and other genes, 
including N-myc and c-myc [35, 190-192]. As a matter of fact, c-myc possesses WT1 binding 
sites in its promoter region and the four major isoforms of WT1 could enhance expression of 
c-myc promoter::luciferase reporter constructs in human breast cancer and leukemia cells. 
The WT1-enhancing activity could be attributed solely to a WT1 binding site upstream of the 
P2 transcription start site of the c-myc promoter, between nucleotides -107 and +36 [35]. 
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Moreover, an enhanced expression of N-myc in Wilms’ tumor cells has been observed [193]. 
Interestingly, there are disparate results concerning the function of WT1, as some studies 
identify it as a tumor-suppressor gene and others as an oncogene. It seems that whether c-myc 
is positively or negatively regulated by WT1 is dependent on the cellular context.   
The discovery of BASP1 as a cosuppressor of WT1 might explain those contradictory 
results. BASP1 binds to an N-terminal suppression region of WT1 spanning WT1 residues 
92-101 and thereby regulates its transcriptional activation domain ranging from WT1 residues 
180-250. Meta-structure analysis of BASP1 and WT1 (chicken and human) as well as meta-
structure based prediction of protein interaction probability and secondary structure of the 
interactor is consistent with the hypothesis that the small stretch of chicken BASP1 residues 
60-80 would bind to the suppression region of WT1 (residues 92-101). BASP1 confers WT1 
cosuppressor activity in transfection assays and elimination of endogenous BASP1 expression 
augments transcriptional activation by WT1. As BASP1 can modulate the function of WT1 
via binding to its suppression domain, it was proposed that in a specific cellular context, the 
WT1-BASP1 interaction may be disrupted or BASP1 may be downregulated to release the 
transcriptional activation function of WT1. Moreover, the cellular localization of BASP1 
might be a possibility to regulate WT1 function [161]. This hypothesis is substantiated by the 
recent finding, that human BASP1 was found to be cleaved and subsequently translocated 
from the nucleus to the cytoplasm of HeLa cells upon induction of apoptosis [162].  
c-myc is a target gene of WT1. Therefore, it might be transcriptionally enhanced by 
WT1 or repressed when in complex with BASP1. It would be interesting to test MC29-
transformed as well as untransformed chicken embryonic fibroblasts (CEF) for WT1 
expression and if chicken BASP1 overexpression reduces endogenous c-Myc expression in 
untransformed CEF.  
The fact that WT1 regulates the transcription of c-myc via binding to its promoter 
region cannot explain the fact that BASP1 hinders transformation by v-Myc as the gene v-
myc encoded by the MC29 proviral genome lacks c-myc promoter regions. It would be 
interesting to test, if WT1 is able to bind to viral promoter regions and thereby influences v-
myc transcription.  
Another possibility assuming the involvement of WT1 in the hindrance of v-Myc 
based transformation is that WT1 in complex with BASP1 leads to the repression of cellular 
genes that might be required for transformation. It has been shown that an elevated expression 
of c-Myc alone is not sufficient for transformation and neoplastic tumor formation and 
requires the deregulation of proteins from distinct pathways (e.g. Ras signaling) [131-133]. 
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Maybe WT1-BASP1 mediated repression of a multitude of target genes and subsequent 
alteration of many different signaling pathways influencing cell behaviour is counteracting 
transformation by v-Myc. 
 
 
Transformation by v-Myc leads to BASP1 repression 
 
Chicken BASP1 has been found to be repressed already at the transcriptional level 
after transformation by oncogenic v-Myc (unpublished data). Myc proteins bind to a lot of 
different promoters – either directly via E-box DNA sequences or indirectly via the 
recruitment by other transcription factors (e.g. Miz1) – and can enhance as well as repress 
transcription of target genes. It would be interesting to search for E-box sequences in 
regulatory regions of cBASP1 to see if Myc proteins would be able to directly bind and 
influence the cBASP1 transcription. Moreover, it would be advisable to search for binding 
sites of other transcription factors that are able to recruit Myc proteins to their target genes. 
For example, one mechanism of Myc-dependent repression involves the recruitment of Myc 
by the normally positive acting factor Miz-1 to initiator elements (INR) in core promoters 
lacking E-box DNA sequences [102, 103]. Moreover, several other factors have been 
suggested to recruit Myc to their cognate DNA binding site (e.g. Sp1, NF-Y, TFII-I and 
yingyang-1 [106-109]).  
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